Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

Active ingredient 'Better gut microbiome function'

Kathrin Cohen Kadosh¹, Melissa Basso^{1*}, Paul Knytl^{1*}, Nicola Johnstone¹, Jennifer Y F Lau², & Glenn Gibson³

¹School of Psychology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK

²Department of Psychology, Institute of Psychiatry Psychology & Neuroscience, King's College London, London, UK

³Department of Food and Nutritional Sciences, The University of Reading, Reading, UK

*Denotes equal contribution

Funding: This project was funded by the Wellcome Trust and conducted in collaboration with the McPin foundation.

Summary

<u>Background</u>: The human gut microbiome and its effect on brain function and mental health is emerging as an area of intensive research. Both animal and human research point towards adolescence as a sensitive period when the gut-brain axis is fine-tuned, and when we can use dietary intervention to change the microbiome, with long-lasting consequences for mental health. Here we report the results of a systematic review/meta-analysis of microbiota-targeted (psychobiotics) interventions on anxiety in youth, together with a summary of consultation work of youth with lived experience.

<u>Methods:</u> Seven databases were searched (no date cut-offs), and controlled trials in clinical and healthy human samples (age range: 10-24) seeking to reduce anxiety were included. All data on between group-differences post intervention and outcomes were extracted as standard mean differences (SMDs) and pooled together based on a random-effects model.

<u>Findings:</u> 5416 studies were identified, 14 were eligible for the qualitative summary, of which 10 were included in the meta-analyses (total of 324 experimental and 293 control subjects). The heterogeneity l² was12% and the pooled SMD was -0.04 (95% CI: -0.21, 0.14). One study presented with low bias risk whereas 5 with high and 4 with uncertain risk, accounting for that, sensitivities analysis revealed a SMD of -0.16 (95%CI: -0.39, 0.06).

<u>Interpretation</u>: There is currently limited evidence for use of psychobiotics to treat anxiety in youth. However, future progress will require a multidisciplinary research approach, which gives priority to specifying mechanisms in the human models, providing causal understanding and addressing the wider context.

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

Introduction

This report summarises our work into the effectiveness of using dietary interventions to improve gut microbiome function in young people aged 14-24 years, with a view to reducing anxiety. It combines results of a systematic review and meta-analysis of the relevant scientific literature with a summary of consultation and focus group work of young people with lived experience of anxiety (N= 45). How does what we eat affect how we feel? Intuitively, it seems right to expect that the one thing that we change about our bodies, on a daily basis, will also have a substantial impact on how we feel. Indeed, in their contribution to this report, just over two thirds of young people with lived experience of clinical levels of anxiety declared that they had previously attempted to influence mental health and well-being with dietary interventions, such as reducing sugar intake or increasing the amount of daily fruit and vegetables eaten, or introducing supplements, such as probiotics and prebiotics, often following the suggestions of family, friends or a GP. For example, Jane¹ said:

"I have anxiety and have been taking probiotics since January for a combo of reasons (gut health, acne, mental health). 100% have noticed a difference and agree that more research in this area is needed".

Mehta added: "I'm really interested in how gut health affects us and I notice it's positive effects personally too, particularly when switching between eating meat and not eating meat and consumption of sugar."

Appreciating the importance of our diet on health and well-being has a long-standing tradition. In a bold statement 2500 years ago, Hippocrates, the father of medicine, stated that *all* disease begins in the gut. A considerable body of research in both human and animal models in the last decade has now largely borne him out, with research repeatedly highlighting the important role that gut microbiota (i.e. the microorganisms that live in the digestive system) play in regulating the brain and subsequent behaviour (Sarkar, Lehto et al. 2016, Sarkar, Harty et al. 2020). This has become a particular research focus within the context of mental health problems such as anxiety or depression (Mayer 2011, Cryan and Dinan 2012, Foster and McVey Neufeld 2013). The gut and the brain are intimately connected via the gut-brain axis, which involves bidirectional communication via neural, endocrine and immune pathways, including the vagus nerve (**Figure 1**), (Grossman 1979, Grenham, Clarke et al. 2011, Mayer, Knight et al. 2014).

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report




Figure 1: Bacteria-Brain-Behaviour Relationships. Gut bacteria communicate with the brain through various channels. The vagus nerve enables bidirectional communication between the gut and brain. Bacteria produce neurotransmitters as metabolites, and these are able to regulate activity in proximal neurons of the enteric nervous system. Bacteria also produce short-chain fatty acids (SCFAs) via the fermentation of non-digestible dietary fibres. SCFAs can modulate neural activity in the host directly, but they also stimulate the release of gut hormones such as glucagon-like peptide 1 (GLP-1) and peptide tyrosine tyrosine (PYY) which control host appetite and satiety. Beneficial bacteria can also trigger the release of anti-inflammatory cytokines which decrease local and systemic inflammation. However, pathogenic bacteria migrating out of the gut (through a weakened gut barrier) trigger proinflammatory cytokine release. Higher levels of inflammation are correlated with depression, and 'leaky gut' is also associated with depression. Furthermore, experiencing stress - and the attendant glucocorticoid response - can also weaken the gut barrier, potentially worsening the inflammatory pathophysiology of emotional disorders. Diet and the use of drugs and antibiotics also directly modulate composition of gut bacteria, which in turn alter the physiological signals generated. Overall, these bacterially generated signals modulate the central nervous system and affect emotion, cognition, and behaviour. Re-printed and adapted with permission from Sarkar, 2018.

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

Animal research has shown that adolescence is a critical window where microbiota help fine- tune the gut-brain axis (McVey Neufeld, Luczynski et al. 2016) and, given the link between the gut-brain axis and mental health could be one factor for a significant increase in mental health problems during this period (Paus, Keshavan et al. 2008, Keshavan, Giedd et al. 2014). This makes a healthy gut microbiome an important and possibly time-sensitive active ingredient, as interventions during this period may have long-lasting consequences both at the gut microbiome and brain level. However, evidence from human participants for the effectiveness of microbiota-targeted interventions to improve mental health is still outstanding.

One effective way of changing the gut microbiome and gut-brain axis is via nutrition, and it has been shown that drastic changes in diet can alter bacterial diversity in days (David, Maurice et al. 2014). Another method for improving the gut microbiome is the use of psychobiotics. Psychobiotics refer to active compounds capable of acting on the nervous system, consequentially shaping psychological processes, behaviour, and ultimately exerting health benefits in psychiatric conditions (Sarkar, Lehto et al. 2016, Sarkar, Harty et al. 2018). Research has also shown that bacterial dysbiosis (i.e. aberrant functioning of different microorganisms in the gut) may lead to the psychological abnormalities that characterise anxiety (Foster and McVey Neufeld 2013). Therefore, manipulation of the gut microbiome via psychobiotics may present a promising new avenue for treatment and prevention of anxiety in young people (Cryan and Dinan 2012, Sarkar, Lehto et al. 2016) (see Figure 2 for a proposed pathway). It is not surprising therefore that the microbiome, and its effect on behaviour and mental health has captured the interest and imagination of scientists, clinicians, health professionals and the wider public alike. As a result, research in this relatively new area has intensified, and young people in particular seem very enthusiastic about this line of research, as they see it as an innovative, approachable and critically a non-stigmatising intervention approach. Sonia wrote in her initial assessment of the consultation:

"This is so interesting. We do not receive many requests on the topic of diet, which is a shame because it was one of top 25 questions in our 'Right People, Right Questions' (RPRQ) project".

Note that the RPRQ project was conducted by the McPin foundation whereby children and young people (including those with lived experience of mental health problems), families, professionals and academics identified the top priorities for research in children and young people's mental health. The fact that diet was selected as a top priority further underlines the importance of gaining a better understanding how it can be used to improve mental health.

In the following, we provide a brief overview of the research conducted in animal models (summarised in **Table 1**) before presenting the results of our systematic review. We will then make

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

6

specific suggestions for future research, which integrate the input by the young people with lived experience.

One class of psychobiotics are known as probiotics - live gut bacteria capable of releasing neuroactive substances (Dinan, Stanton et al. 2013), depending on the bacterial strain. For example, the Bifidobacterium family is linked to GABA expression in the brain, whereas the Enterococcus and Streptococcus families are shown to produce serotonin and Lactobacillus are linked to GABA and acetylcholine (Sarkar et al., 2016). Research has consistently outlined the psychotropic effects of probiotics. For example, in an animal study, Barrett et al. (Barrett, Ross et al. 2012) showed that Lactobacillus (L). brevis and Bifidobacterium (B.) dentium increased GABA concentrations in-vitro, a finding which was replicated in an in-vivo model which showed that a L. brevis ingested strain regulated emotional behavioural and central GABA receptor expression in a mouse model (Bravo, Forsythe et al. 2011). In this study, mice fed L. rhamnosus exhibited reduced GABA mRNA expression in the amygdala, along with lower levels of stress-induced corticosterone and anxietyand depression-related behaviour. Another study replicated this finding (Janik, Thomason et al. 2016) and showed that increases in GABA metabolites in the brain were evident after about 4 weeks, a lag comparable with other pharmaceutical interventions, such as serotonin-reuptake inhibitors (Kodish, Rockhill et al. 2011). Notably, the same study pointed out that re-colonisation of gut bacteria in adolescent germ-free (GF) mice (i.e. mice without any microorganisms living in or on them) was not sufficient to reverse anxiety-like behaviour, once again suggesting that early deficits in gut microbiota may not be reversible.

Along with probiotics, some prebiotics have lately been also classified as psychobiotics. Prebiotics are specific non-digestible food ingredients (including non-digestible oligosaccharides) which selectively feed intrinsic beneficial bacteria, consequentially stimulating their growth and activity with notable effects on brain development and function (Gibson, Scott et al. 2010, Sarkar, Lehto et al. 2016). To date, fructooligosaccharides (FOS) and galactooligosaccharides (GOS) have been the most studied ones, showing promising effects in animal and human trials (Tarr, Galley et al. 2015, Burokas, Arboleya et al. 2017). In the context of cognitive function specifically, Tarr et al. (2015) have shown that milk oligosaccharides administration can prevent stress-induced dysbiosis and anxiety-like behaviour in mice. Likewise, Burokas et al. (2017) have reported chronic combined FOS and GOS supplementation in mice to have anxiolytic and antidepressant effects, as well as to reduce corticosterone stress response. In addition, prebiotics have been shown to modulate hippocampal and hypothalamus gene expression, and lead to SCFAs concentration changes which positively correlate with the behavioural effects.

A further example of the developmental impact of gut microbiome composition on anxiety has recently been demonstrated in a series of animal models. One study reported that rats' ingestion of pre-gestational Lactobacillus helveticus resulted in offspring which then displayed lower rates of anxiety-like behaviour in adolescence (Niu, Liang et al. 2020). In young rats who were experimentally

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

stressed, those who received a placebo presented with abnormal pubertal timing, whilst those fed *Lactobacillus rhamnosus* and *Lactobacillus helveticus* presented normal timing (Cowan and Richardson 2019). In another study, adolescent mice were injected with the toxin lipopolysaccharide which caused immediate and temporary depression- and anxiety-like behaviour, but also increased stress-sensitivity in adulthood. Compared to placebo, mice who received a mixture of *Lactococcus lactis, L. cremoris, L. diacetylactis, L. acidophilus* around the time of toxin administration displayed shorter duration of immediate negative effects and also did not display as severe stress-responses in adulthood (Murray et al., 2019). These findings support an earlier landmark study (Sudo et al., 2004) which found that adult GF mice had enhanced stress responses which could be reversed by gut colonisation with *Bifidobacterium infantis*. Crucially, the earlier in the lifespan this intervention took place, the more fully normal stress response was restored. Thus, if these promising effects translate to humans, psychobiotics present candidate ingredients which could provide a measure of protection against stress-induced anxiety in adolescents which may carry over into adulthood.




Figure 2: Proposed intervention pathway for the active ingredient. Adolescence is a time period of ongoing neuro-cognitive development, allowing brain structures and circuities to flexibly adapt- or maladapt to the environment. In this context, gut microbiota might play be a causal role as a mediator between the environment and the CNS via multiple pathways. As easily manipulated throughout diet, it could be a promising and cheap therapy target in the redirection of neurodevelopmental trajectories and improving the mental health outcome for the individual.

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

Here, we report results of a systematic review and meta-analysis which aimed to determine whether psychobiotics conferred either a protective or restorative effect on anxiety and stress in humans aged 14-24. Seven electronic data bases were searched (Cochrane Library, Embase, Medline, PubMed, Psychinfo, Scopus, and Web of Science) using search terms such as minors, adolescent, child, development, paediatric, puberty, young adult, teen, young men, young women, or undergraduate student (please see **Appendix 1** for a complete description of methods and **Appendix 2** for the full search list). The output of this search was 5416 studies, while subsequent screening provided 14 studies, which measured anxiety or stress either directly or as secondary outcomes (**Figure 3**). The results are summarised in **Table 2** and reviewed below.




Figure 3: PRISMA flowchart of search results at each step of the systematic review.

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

The studies we reviewed were quite heterogeneous in the design of the psychobiotic interventions. In the case of probiotics, many different species were used - sometimes alone and sometimes in combination. Of the 9 probiotic studies, 4 used multiple species of probiotics in the same treatment group and one used up to 18 different species in a group (Tran 2019, Tran, Zhebrak et al. 2019). Across the review, species used included L. plantarum, helveticus, rhamnosus, casei, casei Shirota, paracasei, plantarum, bulgaricus, delbrueckii bulgaricus, acidophilus; B. longum, bifidum, breve, infantis; Saccharomyces boulardii; Streptococcus salivarius thermophilus; and Streptococcus thermophilus. Dose size and frequency and duration of intervention also varied widely. While often on the order of tens of billions of colony-forming units (CFU), doses ranged from 10^9 CFU to 10^11 CFU, once to twice a day from 14 to 56 days. Similarly, a number of different prebiotic compounds were employed: galactooligosaccharide, fructooligosaccharide, omega-3 polyunsaturated fatty acid, and fermented ginseng. Doses of prebiotics were more comparable, ranging from 1.8 g/day to 5.5 g/day for from 8 to 56 days, however study duration was also guite variable from 8 to 56 days. Furthermore, there was a large degree of outcome heterogeneity. When anxiety was measured in the studies, it was with a number of validated instruments such as the Beck Anxiety Inventory (BAI), State-Trait Anxiety Inventory (STAI), Hospital Anxiety and Depression Scale (HADS), or Penn State Worry Questionnaire (PSWQ). Moreover, a variety of stress measures were used, including salivary cortisol, immunoglobulin A, metanephrine, alpha-amylase; self-reported stress; blood pressure; pulse rate; serum cortisol; urinary 8-hydroxydeoxyguanosine; and performance on a behavioural task. Taken together, this heterogeneity is likely due to the novelty of the field, however it makes direct comparison between studies more challenging. Future studies should focus on systematic replications of the findings reported in these studies and, where applicable, confirmation of effective and tolerable doses needs to be assessed.

Perhaps in part because of heterogeneity in methods employed, the review revealed mixed results for the reduction of stress using probiotics in adolescents. Of 6 probiotic studies which measured anxiety, 5 failed to find a significant effect. The remaining study (Tran, Zhebrak et al. 2019) reported both an improvement in PSWQ and paradoxical worsening on the BAI-Panic subscale. Caution is warranted with this study however, since errors in the statistical analysis in the initial manuscript warranted a subsequent correction which significantly altered the initially promising reported outcome (Tran 2019). By far the most common study design for both pre- and probiotics involved following a cohort of selected and unselected university students before, during, and after final exams (Marcos, Warnberg et al. 2004, Andersson, Tullberg et al. 2016, Culpepper, Christman et al. 2016, Kato-Kataoka, Nishida et al. 2016, Kato-Kataoka, Nishida et al. 2016, Takada, Nishida et al. 2016, Karbownik, Kreczynska et al. 2020). These studies often only used stress or anxiety as a secondary outcome, focussing on stress-related GI problems or immune performance, mostly with salivary cortisol as the main outcome. Here, there was some evidence (this assessment is based on

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

the statistical analysis) to support *L. casei Shirota* having protective effects on salivary cortisol and self-reported stress in students approaching final exams (Kato-Kataoka, Nishida et al. 2016, Takada, Nishida et al. 2016). A further study from another group reported reduced stress in sleep deprived students after *B. bifidum* administration during exam periods (Culpepper, Christman et al. 2016). About 50% of studies which measured stress in some way found non-significant effects of their probiotic intervention on stress. One study (Karbownik, Kreczynska et al. 2020) even reported increased pulse rate in the probiotic group (*Saccharomyces boulardii*) which could be interpreted as increased physiological stress, although there was no change in self-reported anxiety.

Taken together, the literature revealed that probiotics used had mixed results reducing stress in youth. This makes sense given the large variety of strains available and tested. Furthermore, the literature currently does not support their use in reducing anxiety, and two studies reported adverse effects, e.g. increased BAI (Tran, Zhebrak et al. 2019) and increased pulse rate (Karbownik, Kreczynska et al. 2020).

Prebiotic interventions

Potentially more promising, but less investigated are prebiotic interventions. Of the five studies that met our inclusion criteria, one using galactooligosaccharide (GOS; (Hughes, Davoodi-Semiromi et al. 2011) found no significant effect on participant stress. Another study of girls with anorexia nervosa (Manos et al., 2018) reported no significant effect of omega-3 polyunsaturated fatty acid (PUFA)² on anxiety as measured by the Beck Anxiety Inventory-trait (BAIT) - however this may have been due to lack of statistical power (n = 18). A larger study also used PUFA as the active ingredient (n = 68; (Kiecolt-Glaser, Belury et al. 2011) but reported reduced BAIT in otherwise healthy university students. Another small study (n = 16) investigating the effects of fermented ginseng (Kitaoka, Uchida et al. 2009) reported reduced total STAI score in healthy university students. Finally, one study using GOS (Schmidt, Cowen et al. 2015) reported both reduced attention to negatively valenced stimuli (hypervigilance to negative stimuli is associated with anxiety and depression) and decreased salivary cortisol (although STAI was unaffected). Furthermore, unpublished work by our lab replicates this vigilance reducing effect of GOS in adolescent females (Johnstone, Milesi et al. under review), along with a reduction in self-reported trait anxiety levels. Interestingly, in this study, a reduction in self-reported anxiety levels (STAIT) was only found in participants with high trait anxiety, which suggests that prebiotic interventions may be most effective in cases where there is already some evidence of microbiome dysbiosis.

² Note that while prebiotic status of PUFA is not yet universally accepted, new evidence supports the inclusion here: Costantini, L., R. Molinari, B. Farinon and N. Merendino (2017). "Impact of Omega-3 Fatty Acids on the Gut Microbiota." Int J Mol Sci **18**(12).

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

Meta-analysis of anxiety outcomes

Of the 14 studies used for the systematic review, 10 were included in the statistical summary (the remaining studies did not assess anxiety but stress only) which was performed with Review Manager 5 (Collaboration 2014). For each study, the standard mean difference (SMD) between the active and control groups was calculated for continuous anxiety outcomes and a Foster plot created (Figure 4). Combination of the SMDs revealed a pooled effect size of -0.04 (95% CI: -0.21, 0.14), pointing towards absence of any intervention effect. However, given that the singular SMDs differed substantially amongst each other, ranging from outcomes showing a consistent between-groups anxiety increase (Kitaoka, Uchida et al. 2009, Manos, Bravender et al. 2018), as well as a significant decrease (Kiecolt-Glaser, Belury et al. 2011), we also performed a sensitivity analysis based on study quality (please see Appendix 3 and Appendix 4 for the complete risk of bias assessment tables) in order to assess whether any other additional variables other than intervention variable might have biased study results. We found that when at high risk of bias studies were excluded, the effect size increased, reaching a value of -0.16 (95% CI: -0.39, 0.06) (Figure 5). It is worth noting that the only study at low risk of bias was that reporting the highest effect size: -0.61 (95% CI: -1.09, -0.12), (Kiecolt-Glaser et al., 2011), whereas the two studies reporting an increase in anxiety (Kitaoka, Uchida et al. 2009, Manos, Bravender et al. 2018) were amongst those at highest risk.

Going forward: recommendations for future research

Based on our systematic review, we conclude that there is currently limited evidence for use of psychobiotics to treat stress and anxiety in youth. As mentioned above, strongest effects may be found in persons with high anxious traits (Johnstone, Milesi et al. under review) and therefore, whereas the vast majority of studies in this review used unselected samples, future studies should involve clinical and borderline clinically anxious populations. There is also a need for more highquality studies which use validated anxiety instruments and behavioural tasks. In particular, it would be important to differentiate whether the intervention aims to improve state and/or trait anxiety, and whether different intervention schedules are required for changing state anxiety as opposed to trait anxiety, for example. Critically, all future studies should include stool sample collections for microbial sequencing to assess direct impacts of intervention on the gut microbiome.

The use of psychobiotics to treat anxiety is a research field still very much in its infancy and given the animal literature and some encouraging preliminary findings in humans (albeit not specifically within the age range chosen for this report), combined with the importance of vulnerability to stress in the adolescent developmental window, we conclude that further research could yield inexpensive, safe and effective means to better manage anxiety. This view is also echoed by young people with lived experience, who not only reported anecdotal evidence of successful psychobiotic interventions, but who also expressed strong interest in contributing to this research drive.

medRxiv preprint doi: https://doi.org/10.1101/2020.11.09.20228445; this version posted December 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

		erimen		-	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Karbownik 2020 STAI-state	52.7	11.45	31	53.1	10.51	29	9.9%	-0.04 [-0.54, 0.47]	+
Kato-Kataoka 2016a STAI-state	49.04	9.95	23	49.96	11.04	23	7.9%	-0.09 [-0.66, 0.49]	+
Kato-Kataoka 2016b STAI-state	48.67	9.61	24	46.39	12.1	23	8.0%	0.21 [-0.37, 0.78]	
Kiecolt Glaser 2011 BAI	0.93	0.44	34	1.2	0.44	34	10.6%	-0.61 [-1.09, -0.12]	-
Kitaoka 2009 STAI total	93.63	17.47	8	84.25	11.37	8	2.8%	0.60 [-0.41, 1.61]	
Liu 2019 CBCL	5.63	4.34	36	5.84	4.41	35	11.4%	-0.05 [-0.51, 0.42]	+
Manos 2018 BAIT	15.4	8.39	10	6.3	7.53	8	2.8%	1.08 [0.07, 2.09]	
Marcos 2004 STAI-state	57.7	31.87	73	65.12	29.44	63	18.6%	-0.24 [-0.58, 0.10]	=
Schmidt 2014 BGOS STAI-state	31.31	5.23	15	30.17	201	15	5.4%	0.01 [-0.71, 0.72]	+
Schmidt 2014 FOS STAI-state	30	5.53	15	30.17	7.55	15	5.4%	-0.02 [-0.74, 0.69]	-+-
Tran 2019 BAI cond.A	7.58	9.16	12	6.2	10.56	10	4.0%	0.14 [-0.71, 0.98]	+
Tran 2019 BAI cond.B	7.61	6.61	13	6.2	10.56	10	4.2%	0.16 [-0.67, 0.99]	
Tran 2019 BAI cond.D	5.86	5.25	15	6.2	10.56	10	4.4%	-0.04 [-0.84, 0.76]	-+-
Tran 2019 BAI cond.E	9.93	11.3	15	6.2	10.56	10	4.3%	0.33 [-0.48, 1.13]	+
Total (95% CI)			324			293	100.0%	-0.04 [-0.21, 0.14]	•
Heterogeneity: Tau ² = 0.01; Chi ² =	= 14.71, d	df = 13 (P = 0.3	33); l ² =	12%				-10 -5 0 5 1

Figure 4: Foster plot of the studies investigating the effect of psychobiotics on anxiety measures.

	Exp	eriment	al	c	ontrol		5	Std. Mean Difference	Std. Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	ABCDEFG
Karbownik 2020 STAI-state	52.7	11.45	31	53.1	10.51	29	19.9%	-0.04 [-0.54, 0.47]	+	$\bullet \bullet \bullet \bullet$
Kato-Kataoka 2016a STAI-state	49.04	9.95	23	49.96	11.04	23	15.2%	-0.09 [-0.66, 0.49]	+	$\bullet \bullet \bullet$
Kato-Kataoka 2016b STAI-state	48.67	9.61	24	46.39	12.1	23	0.0%	0.21 [-0.37, 0.78]		• • • •
Kiecolt Glaser 2011 BAI	0.93	0.44	34	1.2	0.44	34	21.5%	-0.61 [-1.09, -0.12]		
Kitaoka 2009 STAI total	93.63	17.47	8	84.25	11.37	8	0.0%	0.60 [-0.41, 1.61]		
Liu 2019 CBCL	5.63	4.34	36	5.84	4.41	35	23.5%	-0.05 [-0.51, 0.42]	+	$\bullet \bullet \bullet \bullet$
Manos 2018 BAIT	15.4	8.39	10	6.3	7.53	8	0.0%	1.08 [0.07, 2.09]		
Marcos 2004 STAI-state	57.7	31.87	73	65.12	29.44	63	0.0%	-0.24 [-0.58, 0.10]		θ. \varTheta
Schmidt 2014 BGOS STAI-state	31.31	5.23	15	30.17	201	15	9.9%	0.01 [-0.71, 0.72]	+	•
Schmidt 2014 FOS STAI-state	30	5.53	15	30.17	7.55	15	9.9%	-0.02 [-0.74, 0.69]	+	•
Tran 2019 BAI cond.A	7.58	9.16	12	6.2	10.56	10	0.0%	0.14 [-0.71, 0.98]		••
Tran 2019 BAI cond.B	7.61	6.61	13	6.2	10.56	10	0.0%	0.16 [-0.67, 0.99]		
Tran 2019 BAI cond.D	5.86	5.25	15	6.2	10.56	10	0.0%	-0.04 [-0.84, 0.76]		
Tran 2019 BAI cond.E	9.93	11.3	15	6.2	10.56	10	0.0%	0.33 [-0.48, 1.13]		••
Total (95% CI)			154			151	100.0%	-0.16 [-0.39, 0.06]	•	
Heterogeneity: Tau ² = 0.00; Chi ² =	4.10, df	= 5 (P =	= 0.54)	l ² = 0%	6					
Test for overall effect: Z = 1.42 (P	= 0.16)		,						-10 -5 0 5 decrease in anxiety increase in anxie	10 ty
									-	
Risk of bias legend	(
(A) Random sequence generation	,									
(B) Allocation concealment (select										
(C) Blinding of participants and pe				ias)						
(D) Blinding of outcome assessme			s)							
(E) Incomplete outcome data (attri)								
(F) Selective reporting (reporting b)	las)									

Figure 5: Foster plot excluding the studies at high risk of bias. Reasons for high risk are as follows: **A**. Marcos et al. (2004): concerns in regards to the randomization and allocation sequence and nonblinded design; **B**. Kitaoka et al. (2009): unclear anxiety score differences at baseline between the active and control group, absence of a participants flow diagram and of any relevant information about intervention adherence and missing data; **C**. Manos et al. (2018): unclear anxiety score differences at baseline between active (severe anxiety levels) and control (moderate anxiety levels) groups, not specified reasons for no intervention adherence and missing data, no measurement of state anxiety; **D**. Kato-Kataoka et al. (2016b): no randomized allocation, significantly different anxiety scores at baseline (p<0.05) between the active and control group; **E**. Tran et al. (2019): concerns in regard with randomization and allocation process, not enough information about adherence to the intervention and missing data, concerns about the performed statistical analyses.

Young people with lived experience request clearer instructions

Based on the literature, it would appear that specifically, consumption of *L. casei Shirtoa, L. rhamnosus, L. helveticus*, and *Bifidobacterium* (e.g. *B. infantis*) may provide some protection from the anxiogenic effects of environmental stress, and further long-term studies examining whether the development of anxious traits could be partially ameliorated by these probiotics. The young people noted that such information and guidance on specific bacterial strains would be welcome as the vast number of commercially available probiotic combinations are very confusing. As Becky put it:

"When I go into Boots to buy probiotics, there are millions of products available and the prices vary hugely, so I simply don't know what to choose and I end up getting nothing. It would really help to receive some clarifications on what actually works".

As evident from the review above and the meta-analysis, prebiotics hold particular promise as they are non-digestible (fibre) and thus, unlike some probiotics, reliably arrive fully in the gut. Best bets for further study are GOS and fructooligosaccharides which stimulate growth of beneficial *Lactobacillus* and *Bifidobacterium* species. These compounds are also more stable and not subject to the same degradation in potency over time that can be problematic in probiotics. Prebiotics such as FOS make up part of the dietary fibre in naturally occurring foods such as dairy, or are now widely available in concentrated form as food additives or supplements (Lamsal, 2012), which start from around £10 for a month supply.

Psychobiotic interventions could benefit from existing cultural practises

One advantage of psychobiotics in the treatment and prevention of youth anxiety that may have been as yet overlooked is the existing cross-cultural prevalence of fermented food sources containing psychobiotics. For instance, anxiolytic strains of *lactobacilli* have been found in traditional fermented doughs from the Congo and Burkina Faso (Abriouel, Ben Omar et al. 2006), Japanese fermented fish (Komatsuzaki, Shima et al. 2005), dairy and pickles from China and Mongolia (Bao, Song et al. 2016), and eastern European *kefir* fermented milk (Simova, Beshkova et al. 2002). This means that anxiolytic psychobiotics consumption could be ripe for a behavioural 'nudge', given that these products exist widely in many cultures and therefore potentially present fewer cultural barriers to use.

Young people would like to understand 'the bigger picture'

Young people with lived experience showed much enthusiasm and support for more research in the area of dietary interventions, especially in light of the current gap for the age range of 14-24 years. However, they also asked for research approaches that would look at the bigger picture, which could include information on an individual's personal circumstances and living situation. What was

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

specifically discouraged was yet another prescriptive approach that would require a change in diet, irrespective of other factors such as educational pressure, work environment aspects such as shift work, sleeping patterns, exercise or a number of other, common comorbidities such as depression. Based on our systematic review, we very much agree with the young people and would like to suggest that one possible explanation for the current success of psychobiotic interventions in animal research is that these studies have maximal control over all these different factors through the use of large, longitudinal cohorts and optimal control of environmental factors, whereas human studies either have chosen not to address these potentially confounding variables or been unable to do so.

Sample-specific considerations for future research

The young people provided a number of important suggestions with regards to new research going forward. For example, when discussing different confounding factors, they stressed repeatedly that any data collection on nutritional intake would need to proceed with caution. Specifically, it was warned that providing participants with numerical feedback, such as total calories consumed per day, would easily trigger attempts to control these numbers, as any potential mechanism of control would be latched upon, with potentially far reaching consequences, such as the risk of developing an eating disorder. The young people conceded that while it would be important to obtain comprehensive data on nutritional intake and dietary habits, it would be more helpful to withhold specific detailed feedback and only provide general pointers about nutritional health for example. Last, the young people stated that providing faeces for microbiome sequencing could be a real obstacle for this kind of research, but that they would consider participating if there were a number of options available for stool sampling (i.e. at home or at a testing centre), and that discretion (e.g. packaging for the stool sample that would be both leak and smell-proof, as well as neutrally designed) was paramount. These are all very valuable points as both nutritional analyses, as well as microbiome sequencing are both cornerstones of dietary intervention research into the microbiome gut-brain axis.

Towards a new, multidisciplinary research approach

Going forward, it is our view that in order to future-proof this new research area and to allow for sustained scientific progress and breakthrough, what is now needed are systematic, multidisciplinary approaches that consider not only the effect of the dietary intervention on composition of the microbiome, but also on how interventions interact with ongoing brain maturation and functional responsiveness. Similarly, and in line with the important points highlighted by the young people in our consultation, other factors such as hormonal changes due to the specific puberty stage or menstrual cycle, sleep hygiene and patterns, as well as life-style factors such as nutrition and exercise will need to be included to obtain a comprehensive, 'bigger picture'. Such an approach would also increase uptake and compliance with any future interventions.

15

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

Future studies could adopt a research approach that is already practised in the field of developmental cognitive neuroscience (DCN) (Johnstone and Cohen Kadosh in press), which focuses on investigating how the complex interplay of genetic, environmental and brain maturational factors shape psychological functioning in development to improve outcomes for the individual (Johnson, Halit et al. 2002, Johnson, Grossmann et al. 2009, Cohen Kadosh 2011). Moreover, placed at the intersection of nature vs. nurture, the DCN research approach always assumes a multi-level and multi-factor approach to understanding change which, by definition is multidisciplinary. Given that the field of microbiome and gut-brain axis research is still emerging and finding its shape, we would like to stress that any real progress will depend on the adoption of a similarly comprehensive multifactorial and multidisciplinary research approach for pinpointing mechanisms and translation in both animal and human models. Therefore, priority for funding should be given to projects that bring together the expertise and the collaboration of scientists from a range of fields (education, psychology, microbiology, neuroscience, and nutrition) and, importantly, guidance and advice from young people with lived experience to ensure that all research continues to address the questions that are relevant to the lives of young people with anxiety.

To conclude, the gut microbiome, and its effect on behaviour and mental health has captured the interest and imagination of scientists and the wider public alike. However, as a still relatively unexplored area, any real progress will require a multidisciplinary research approach, which gives priority to specifying mechanisms in the human and animal models, providing causal understanding and addressing realistic outcomes. This is particularly critical in light of strong public and commercial interests that are presently outpacing research efforts. Encouragingly, this approach has also been met with much enthusiasm from young people with lived experience of mental health problems, which suggests that these research approach and interventions may be ripe for a behavioural 'nudge' and potentially present few cultural barriers to use.

References

Abriouel, H., N. Ben Omar, R. L. Lopez, M. Martinez-Canamero, S. Keleke and A. Galvez (2006). "Culture-independent analysis of the microbial composition of the African traditional fermented foods poto poto and degue by using three different DNA extraction methods." <u>Int J Food Microbiol</u> **111**(3): 228-233.

Andersson, H., C. Tullberg, S. Ahrne, K. Hamberg, I. Lazou Ahren, G. Molin, M. Sonesson and A. Hakansson (2016). "Oral Administration of Lactobacillus plantarum 299v Reduces Cortisol Levels in Human Saliva during Examination Induced Stress: A Randomized, Double-Blind Controlled Trial." Int J Microbiol **2016**: 8469018.

Bao, Q., Y. Song, H. Xu, J. Yu, W. Zhang, B. Menghe, H. Zhang and Z. Sun (2016). "Multilocus sequence typing of Lactobacillus casei isolates from naturally fermented foods in China and Mongolia." <u>J Dairy Sci</u> **99**(7): 5202-5213.

Barrett, E., R. P. Ross, P. W. O'Toole, G. F. Fitzgerald and C. Stanton (2012). "gamma-Aminobutyric acid production by culturable bacteria from the human intestine." <u>J Appl Microbiol</u> **113**(2): 411-417.

Bravo, J. A., P. Forsythe, M. V. Chew, E. Escaravage, H. M. Savignac, T. G. Dinan, J. Bienenstock and J. F. Cryan (2011). "Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve." <u>Proc Natl Acad Sci U S A</u> **108**(38): 16050-16055.

Burokas, A., S. Arboleya, R. D. Moloney, V. L. Peterson, K. Murphy, G. Clarke, C. Stanton, T. G. Dinan and J. F. Cryan (2017). "Targeting the Microbiota-Gut-Brain Axis: Prebiotics Have Anxiolytic and Antidepressant-like Effects and Reverse the Impact of Chronic Stress in Mice." <u>Biol Psychiatry</u> **82**(7): 472-487.

Cohen Kadosh, K. (2011). "What can emerging cortical face networks tell us about mature brain organisation?" <u>Developmental Cognitive Neuroscience</u> **1**(3): 246-255.

Collaboration, T. C. (2014). Review Manager (RevMan). Copenhagen, The Nordic Cochrane Centre.

Costantini, L., R. Molinari, B. Farinon and N. Merendino (2017). "Impact of Omega-3 Fatty Acids on the Gut Microbiota." Int J Mol Sci **18**(12).

Cowan, C. S. M. and R. Richardson (2019). "Early-life stress leads to sex-dependent changes in pubertal timing in rats that are reversed by a probiotic formulation." <u>Dev Psychobiol</u> **61**(5): 679-687.

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

Cryan, J. F. and T. G. Dinan (2012). "Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour." <u>Nat Rev Neurosci</u> **13**(10): 701-712.

Culpepper, T., M. C. Christman, C. Nieves, Jr., G. J. Specht, C. C. Rowe, S. J. Spaiser, A. L. Ford, W. J. Dahl, S. A. Girard and B. Langkamp-Henken (2016). "Bifidobacterium bifidum R0071 decreases stress-associated diarrhoea-related symptoms and self-reported stress: a secondary analysis of a randomised trial." <u>Benef Microbes</u> **7**(3): 327-336.

David, L. A., C. F. Maurice, R. N. Carmody, D. B. Gootenberg, J. E. Button, B. E. Wolfe, A. V. Ling, A. S. Devlin, Y. Varma, M. A. Fischbach, S. B. Biddinger, R. J. Dutton and P. J. Turnbaugh (2014). "Diet rapidly and reproducibly alters the human gut microbiome." <u>Nature</u> **505**(7484): 559-563.

Dinan, T. G., C. Stanton and J. F. Cryan (2013). "Psychobiotics: a novel class of psychotropic." <u>Biol Psychiatry</u> **74**(10): 720-726.

EPPI-Centre, D. S. F. a. (2020). EPPI-Mapper. London, UK, University College London.

Foster, J. A. and K. A. McVey Neufeld (2013). "Gut-brain axis: how the microbiome influences anxiety and depression." <u>Trends Neurosci</u> **36**(5): 305-312.

Gibson, G. R., E. S. Scott, R. A. Rastall, K. M. Tuohy, A. Hotchkiss, A. Dubert-Ferrandon, M.
Gareau, E. F. Murphy, D. Saulnier, G. Loh, S. Macfarlane, N. Delzenne, Y. Ringel, G. Kozianowski,
R. Dickmann, I. Lenoir-Wijnkoop, C. Walker and R. Buddington (2010). "Dietary prebiotics: current status and new definition." Food Science and Technology 7(1): 1-19.

Grenham, S., G. Clarke, J. F. Cryan and T. G. Dinan (2011). "Brain-gut-microbe communication in health and disease." <u>Frontiers in Physiology</u> **2**: 94.

Grossman, M. I. (1979). "Neural and hormonal regulation of gastrointestinal function: an overview." <u>Annu Rev Physiol</u> **41**: 27-33.

Higgins, J. P., S. G. Thompson, J. J. Deeks and D. G. Altman (2003). "Measuring inconsistency in meta-analyses." <u>BMJ</u> **327**(7414): 557-560.

Hughes, C., Y. Davoodi-Semiromi, J. C. Colee, T. Culpepper, W. J. Dahl, V. Mai, M. C. Christman and B. Langkamp-Henken (2011). "Galactooligosaccharide supplementation reduces stress-induced gastrointestinal dysfunction and days of cold or flu: a randomized, double-blind, controlled trial in healthy university students." <u>Am J Clin Nutr</u> **93**(6): 1305-1311.

Janik, R., L. A. M. Thomason, A. M. Stanisz, P. Forsythe, J. Bienenstock and G. J. Stanisz (2016). "Magnetic resonance spectroscopy reveals oral Lactobacillus promotion of increases in brain GABA, N-acetyl aspartate and glutamate." <u>Neuroimage</u> **125**: 988-995.

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

Johnson, M. H., T. Grossmann and K. Cohen Kadosh (2009). "Mapping functional brain development: Building a social brain through interactive specialization." <u>Dev Psychol</u> **45**(1): 151-159.

Johnson, M. H., H. Halit, S. J. Grice and A. Karmiloff-Smith (2002). "Neuroimaging of typical and atypical development: a perspective from multiple levels of analysis." <u>Dev Psychopathol</u> **14**(3): 521-536.

Johnstone, N. and K. Cohen Kadosh (in press). "Why a developmental cognitive neuroscience approach may be key for future-proofing microbiota-gut-brain research: commentary on Microbiota-gut-brain research: a critical analysis. ." <u>Brain and Behavioural Sciences</u>.

Johnstone, N., C. Milesi, O. Burn, T. van den Borgert, K. Hart, P. T. Sowden, P. Burnet and K. Cohen Kadosh (under review). "Anxiolytic effects of a prebiotic in healthy female volunteers are associated with reduced negative bias and increases in 'helpful' bacteria in the gut. ."

Karbownik, M. S., J. Kreczynska, P. Kwarta, M. Cybula, A. Wiktorowska-Owczarek, E. Kowalczyk, T. Pietras and J. Szemraj (2020). "Effect of Supplementation with Saccharomyces Boulardii on Academic Examination Performance and Related Stress in Healthy Medical Students: A Randomized, Double-Blind, Placebo-Controlled Trial." <u>Nutrients</u> **12**(5).

Kato-Kataoka, A., K. Nishida, M. Takada, M. Kawai, H. Kikuchi-Hayakawa, K. Suda, H. Ishikawa, Y. Gondo, K. Shimizu, T. Matsuki, A. Kushiro, R. Hoshi, O. Watanabe, T. Igarashi, K. Miyazaki, Y. Kuwano and K. Rokutan (2016). "Fermented Milk Containing Lactobacillus casei Strain Shirota Preserves the Diversity of the Gut Microbiota and Relieves Abdominal Dysfunction in Healthy Medical Students Exposed to Academic Stress." <u>Appl Environ Microbiol</u> **82**(12): 3649-3658.

Kato-Kataoka, A., K. Nishida, M. Takada, K. Suda, M. Kawai, K. Shimizu, A. Kushiro, R. Hoshi, O. Watanabe, T. Igarashi, K. Miyazaki, Y. Kuwano and K. Rokutan (2016). "Fermented milk containing Lactobacillus casei strain Shirota prevents the onset of physical symptoms in medical students under academic examination stress." <u>Benef Microbes</u> **7**(2): 153-156.

Keshavan, M. S., J. Giedd, J. Y. Lau, D. A. Lewis and T. Paus (2014). "Changes in the adolescent brain and the pathophysiology of psychotic disorders." <u>Lancet Psychiatry</u> **1**(7): 549-558.

Kiecolt-Glaser, J. K., M. A. Belury, R. Andridge, W. B. Malarkey and R. Glaser (2011). "Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial." <u>Brain Behav Immun</u> **25**(8): 1725-1734.

Kitaoka, K., K. Uchida, N. Okamoto, S. Chikahisa, T. Miyazaki, E. Takeda and H. Sei (2009). "Fermented ginseng improves the first-night effect in humans." <u>Sleep</u> **32**(3): 413-421.

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

Kodish, I., C. Rockhill and C. Varley (2011). "Pharmacotherapy for anxiety disorders in children and adolescents." <u>Dialogues Clin Neurosci</u> **13**(4): 439-452.

Komatsuzaki, N., J. Shima, S. Kawamoto, H. Momose and T. Kimura (2005). "Production of γaminobutyric acid (GABA) by Lactobacillus paracasei isolated from traditional fermented foods." <u>Food Microbiology</u> **22**(6): 497-504.

Manos, B. E., T. D. Bravender, T. M. Harrison, H. L. H. Lange, C. B. Cottrill, M. Abdel-Rasoul and A. E. Bonny (2018). "A pilot randomized controlled trial of omega-3 fatty acid supplementation for the treatment of anxiety in adolescents with anorexia nervosa." <u>Int J Eat Disord</u> **51**(12): 1367-1372.

Marcos, A., J. Warnberg, E. Nova, S. Gomez, A. Alvarez, R. Alvarez, J. A. Mateos and J. M. Cobo (2004). "The effect of milk fermented by yogurt cultures plus Lactobacillus casei DN-114001 on the immune response of subjects under academic examination stress." <u>Eur J Nutr</u> **43**(6): 381-389.

Mayer, E. A. (2011). "Gut feelings: the emerging biology of gut-brain communication." <u>Nat Rev</u> <u>Neurosci</u> **12**(8): 453-466.

Mayer, E. A., R. Knight, S. K. Mazmanian, J. F. Cryan and K. Tillisch (2014). "Gut microbes and the brain: paradigm shift in neuroscience." <u>J Neurosci</u> **34**(46): 15490-15496.

McVey Neufeld, K. A., P. Luczynski, C. Seira Oriach, T. G. Dinan and J. F. Cryan (2016). "What's bugging your teen?-The microbiota and adolescent mental health." <u>Neurosci Biobehav Rev</u> **70**: 300-312.

Niu, Y., S. Liang, T. Wang, X. Hu, W. Li, X. Wu and F. Jin (2020). "Pre-Gestational intake of Lactobacillus helveticus NS8 has anxiolytic effects in adolescent Sprague Dawley offspring." <u>Brain</u> <u>Behav</u>: e01714.

Paus, T., M. Keshavan and J. N. Giedd (2008). "Why do many psychiatric disorders emerge during adolescence?" <u>Nature Reviews Neuroscience</u> **9**: 947-957.

Sarkar, A., S. Harty, K. V. Johnson, A. H. Moeller, R. N. Carmody, S. M. Lehto, S. E. Erdman, R. I. M. Dunbar and P. W. J. Burnet (2020). "The role of the microbiome in the neurobiology of social behaviour." <u>Biol Rev Camb Philos Soc</u>.

Sarkar, A., S. Harty, S. M. Lehto, A. H. Moeller, T. G. Dinan, R. I. M. Dunbar, J. F. Cryan and P. W. J. Burnet (2018). "The Microbiome in Psychology and Cognitive Neuroscience." <u>Trends Cogn Sci</u> **22**(7): 611-636.

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

Sarkar, A., S. M. Lehto, S. Harty, T. G. Dinan, J. F. Cryan and P. W. J. Burnet (2016). "Psychobiotics and the Manipulation of Bacteria-Gut-Brain Signals." <u>Trends Neurosci</u> **39**(11): 763-781.

Schmidt, K., P. J. Cowen, C. J. Harmer, G. Tzortzis, S. Errington and P. W. Burnet (2015). "Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers." <u>Psychopharmacology (Berl)</u> **232**(10): 1793-1801.

Simova, E., D. Beshkova, A. Angelov, T. Hristozova, G. Frengova and Z. Spasov (2002). "Lactic acid bacteria and yeasts in kefir grains and kefir made from them." <u>J Ind Microbiol Biotechnol</u> **28**(1): 1-6.

Sterne, J. A. C., J. Savovic, M. J. Page, R. G. Elbers, N. S. Blencowe, I. Boutron, C. J. Cates, H. Y. Cheng, M. S. Corbett, S. M. Eldridge, J. R. Emberson, M. A. Hernan, S. Hopewell, A. Hrobjartsson, D. R. Junqueira, P. Juni, J. J. Kirkham, T. Lasserson, T. Li, A. McAleenan, B. C. Reeves, S. Shepperd, I. Shrier, L. A. Stewart, K. Tilling, I. R. White, P. F. Whiting and J. P. T. Higgins (2019).
"RoB 2: a revised tool for assessing risk of bias in randomised trials." <u>BMJ</u> 366: I4898.

Takada, M., K. Nishida, A. Kataoka-Kato, Y. Gondo, H. Ishikawa, K. Suda, M. Kawai, R. Hoshi, O. Watanabe, T. Igarashi, Y. Kuwano, K. Miyazaki and K. Rokutan (2016). "Probiotic Lactobacillus casei strain Shirota relieves stress-associated symptoms by modulating the gut-brain interaction in human and animal models." <u>Neurogastroenterol Motil</u> **28**(7): 1027-1036.

Tarr, A. J., J. D. Galley, S. E. Fisher, M. Chichlowski, B. M. Berg and M. T. Bailey (2015). "The prebiotics 3'Sialyllactose and 6'Sialyllactose diminish stressor-induced anxiety-like behavior and colonic microbiota alterations: Evidence for effects on the gut-brain axis." <u>Brain Behav Immun</u> **50**: 166-177.

Tran, N. (2019). "Updated statistic to the gut-brain paper examining the effect of multispecies probiotics on anxiety score in young adults: A response." <u>J Affect Disord</u> **259**: 314-315.

Tran, N., M. Zhebrak, C. Yacoub, J. Pelletier and D. Hawley (2019). "The gut-brain relationship: Investigating the effect of multispecies probiotics on anxiety in a randomized placebo-controlled trial of healthy young adults." <u>J Affect Disord</u> **252**: 271-277.

	Table 1. C	Characteristics	of the pre	e-clinical int	ervention	studies
--	------------	-----------------	------------	----------------	-----------	---------

Study	animal	Intervention	Active Compound	Dose	Frequency (dose/day)	Duration (days)	sex	age (weeks)	behavioural anxiety measure	effect	stress measures	effect	neurobiological measures	effect
Study	ammai	intervention	Active compound	Dose	(uose/uuy)	(uuys)	367	(weeks)	measure	enect	stress measures	enect	measures	个CG1, PrL
			Lactobacillus											↓BLA, CeA, LC
Bravo et al. (2011)	mice	probiotic	rhamnosus (JB-1)	5 x 10^9 CFU	1	28	male	10/11	EPM	↑open arms	Corticosterone	\checkmark	GABA B1B mRNA	DG, CA3, CA1
51440 61 41. (2011)	mee	problotic	(ib 1)	5 × 10 5 0 0	-	20	mare	10, 11	2.101	1 open anns	controsterone	¥	G/ B/ BID III (I/	20, 0, 0, 0, 0, 0
											SIH	ns		
										↑ time in the				
Burokas et al. (2017)	mice	prebiotic	FOS	0.3-0.4 g	1	70	male	>7	OFT	centre	SIH	↓ FOS+GOS	GABA B1	个FOS+GOS
· · · ·				0						↓buried				
			GOS						defensive marble burying	marbles	corticosterone	\checkmark	GABA B2	个FOS+GOS
										↑entries into	stress-induced	↓GOS and		↑hippocampus
			FOS+GOS						EPM	the centre	defecation	GOS+FOS	BDNF	FOS+GOS
			placebo											
			Lactobacillus											
Janik et al. (2016)	mice	probiotic	rhamnosus (JB-1)	1 x 10^9 CFU	1	28	male	adult	-	-	-	-	GABA metabolites	\uparrow
Tarr et al. (2015)	mice	prebiotic	3'Sialyllactose	5% of diet	1	14	male	6-8	light-dark transition	↑dark	corticosterone	ns	-	-
										个time in the				
			6'Sialyllactose						OFT	centre				
			Lactobacillus				male and							
Niu et al. (2019)	SPF rats	probiotic	helveticus NS8	10^8 CFU/ml	1	9	female	9	EPM	↑open arms	-	-	-	-
										↑ time in the				
										centre				
										↑entries into				
										the centre				
									OFT	↓latency				
									PPI	ns				
			Lactobacillus											
			cremoris,											
			Lactobacillus											
			diacetylactis,											
			Lactobacillus				male and			↑open arms,	Restraint stress			
Murray et al. (2019)	mice	probiotic	acidophilus	3 x 10^9 CFU/	g 1	14	female	5-7	EPM	males ↑ time in the	test	-	-	•
									OFT	centre, males				
							male and			centre, males				
Kitaoka et al. (2009)	mice	prebiotic	fermented ginseng	50 mg/kg	1	20	female		light-dark transition	↓latency	-	-	GAT1	\checkmark
(2003)	muc	prebiotic	i cimente a ginsellig	50 mg/ mg	-	20	remare	,	ingine dank transition	winchey			0,111	¥

CG1: cingulate cortex 1; PrL: prelimbic; BLA: basolateral amygdala; CeA: central amygdala; LC. Locus coeruleus; DG: dentate gyrus; CA3: cornus ammonis area 3; CA1: cornus ammonis area 1; OFT: open field test; EPM: elevated plus maze; SIH: stressinduced hypertermia; SPF: specific-pathogen-free; PPI: prepulse inhibition; GAT1: predominant GABA transporter; Abat: GABA catabolic enzyme

Study	Intervention Type	Delivery Method	Active Compound	Dose	Frequency (dose/day)		Active/ Control	Mean Age (SE)	Sex (M/F)	Anxiety Measure	Effect	Stress Measure	Effect2
Andersson et al. (2016)	probiotic	capsule	Lactobacillus plantarum 299v	10 x 10^9 CFU	1	21	21/20	range 18-30	13/28	-	-	salivary cortisol	\downarrow
												salivary immunoglobulin A	ns
Culpepper et al. (2016) p	probiotic	capsule	Lactobacillus helveticus R0052	3 × 10^9 CFU	1	42	145	19.9 (0.1)	209/372	-	-	self-reported stress	↓ for B. Bifidum only, only in sleep deprived students
			Bifidobacterium longum ssp. infantis R0033				147						
			Bifidobacterium bifidum R0071				142						
			placebo				147						
Hughes et al. (2011)	prebiotic	sachet	galactooligosaccharide	0, 2.5, 5 g	1	56	279/14 0	19.9 (0.1)	207/212	-	-	self-reported stress	ns
Karbownik et al. (2020)	probiotic	capsule	Saccharomyces boulardii	5 x 10^9 CFU	1	30	31/29	22.6	37/55	STAI state	ns	salivary cortisol	ns
												salivary metanephrine	ns
Kato-Kataoka et al. (2016)	probiotic	liquid	Lactobacillus casei Shirota	100 x 10^9	1	56	23/24	22.8 (0.4)	25/22	STAI state	ns	pulse rate visual analogue	<u>↑</u> ↓
	problotic	iiquiu		CFU	I	50	25/24	22.8 (0.4)	25/22	STATState	115	stress scale	
												salivary cortisol	\checkmark
												salivary alpha- amylase	ns
Kato-Kataoka et al. (2016b)	probiotic	liquid	Lactobacillus casei Shirota	100 x 10^9 CFU	1	56	24/23	22.9 (0.4)	26/21	STAI state	ns	salivary cortisol	ns
										HADS	-	salivary immunoglobulin A	ns
Kitaoka et al. (2009)	prebiotic	capsule	Fermented Ginseng	205 mg	9	8	8/8	20.7 (0.4)	16/0	STAI total	\downarrow	salivary cortisol	ns
			C C	0			·	. ,		POMS	ns	salivary immunoglobulin A	ns
												urinary 8-	ns
												hydroxydeoxyguano	
												sine	

Table 2. Characteristics of the studies included in the systematic review

(continued)

Church .	Intervention		Asting Commonweal	Deve	Frequency		Active/	Maran Ara (CC)	C (D A /E)	Anxiety	Ff ()	64	54
Study	Туре	Method	Active Compound	Dose	(dose/day)			Mean Age (SE)		Measure	Effect	Stress Measure	Effect2
Kiecolt-Glaser et al. (2011)	prebiotic	capsule	omega-3 polyunsaturated	2.5 g	1	84	34/34	23.7 (1.9)	38/30	BAI	\downarrow	-	-
Live at al. (2010)			fatty acid	201040		20	26/25	10.0	74./0	CRCI			
Liu et al. (2019)	probiotic	capsule	Lactobacillus plantarum	30 x 10^9	ns	30	36/35	10.0	71/0	CBCL	ns	-	-
NA 1 (2010)			PS128	CFU			10/0		0/40				
Manos et al. (2018)	prebiotic	capsule	omega-3-PUFA	782 mg	4	84		14.7	0/18	BAIT	\downarrow	-	-
Marcos et al. (2004)	probiotic	liquid	Lactobacillus delbrueckii	1 x 10^9	2	21	73/63	18-23	40/96	STAI state	ns	serum cortisol	ns
			bulgaricus	CFU									
			Streptococcus salivarius	10 x 10^9						STAI trait	ns		
			thermophilus	CFU									
			Lactobacillus casei DN114001										
				CFU									
Moller et al. (2017)	probiotic	capsule	Bifidobacterium breve		1	14	57/48	20.2	36/69	-	-	PASAT	ns
				10^9 CFU									
				(total)									
			B.longum									Blood pressure	ns
			B. infantis										
			Lactobacillus acidophilus										
			L. plantarum										
			L. paracasei										
			L. bulgaricus										
			Streptococcus thermophilus										
Schmidt et al. (2014)	prebiotic	powder	fructooligosaccharides (FOS)	5.5 g	1	21	15	23.7	22/23	STAI state	ns	PSS-10	ns
			galactooligosaccharide (B-				15			Attentional dot-	↓GOS only,	salivary cortisol	↓ GOS only
			GOS)							probe	unmasked	•	
			placebo				15			Facial	ns		
										expression			
										recognition			
										Emotional word	ns		
										recognition and			
										recall			
										ICCOL			

Table 2. Characteristics of the studies included in the systematic review (cont'd)

(continued)

	Intervention	Delivery			Frequency	Duration	Active/			Anxiety			
Study	Туре	Method	Active Compound	Dose	(dose/day)	(days)	Control	Mean Age (SE)	Sex (M/F)	Measure	Effect	Stress Measure	Effect2
Tran et al. (2019)	probiotic	-	18 species	50 x 10^9 CFU	1	28	14	20.6	20/66	BAI	ns BAI total ↑ BAI-Panic, 50 x 10^9 CFU only	-	-
			10 species	50 x 10^9 CFU			13			ACQ-R	-		
			18 species	15 x 10^9 CFU			15			PSWQ	↓50 x 10^9 CFU only		
			10 species	10 x 10^9 CFU			15						
			placebo				11						

Table 2. Characteristics of the studies included in the systematic review (cont'd)

↓: improvement vs placebo; ↑: deminishment vs placebo; *: effect size estimated or calculated from reported data; ns: no significant effect; -: not reported or not applicable; ACQ-R: Anxiety control questionnaire-revised; BAI: Beck Anxiety Inventory; CBCL: Child Behaviour Checklist (Anxiety); CFU: colony forming units; HADS: Hospital Anxiety and Depression Scale; PASAT: Paced Auditory Serial Addition Test; PSS: Percieved Stress Scale-10; PSWQ: Penn state worry questionnaire; STAI: State-Trait Anxiety Inventory

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

Appendix 1: methods

Eligibility criteria

Participants

Only studies whose participants mean age fell within the age range of 10-24 years old were included, regardless of gender, religious, ethnicity and socio-demographic status. Both healthy and clinical samples were eligible, as far as either anxiety or stress were measured.

Study and intervention type

Only controlled trials that had assessed anxiety and stress as primary or secondary outcome were searched. At least two measures- one pre- and one post- intervention, needed to have been collected. No selection criteria were considered for follow-up and settings. Studies based on either prebiotics or probiotics supplements intake were included, regardless of the form they were administered in- tablets, powders, capsules, fortified food, food, drinks. Studies assessing probiotics and prebiotics-based interventions in combination between with each other (i.e. synbiotics) were excluded.

Comparators

Both placebo and treatment as usual comparison groups were eligible.

Outcomes

Primary outcome

Overall anxiety symptoms improvement as assessed by the included studies. Validated-self reported anxiety measures and questionnaires as well as structured and semi-structured interviews were eligible.

Secondary outcome

Behavioural (as assessed by e.g. emotional stroop, dot-probe, speech test) as well as stress measures were eligible.

Report criteria

Studies fulfilling the following criteria were included: data did not necessarily have to be available, but needed to be published and peer-reviewed. No restrictions were applied for date of publication.

Search strategy

7 databases were searched (PubMed, Embase, Cochrane, Scopus, Ovid, Orbis, Web of Science) and the search strategies reported in the <u>Appendix 2</u> were implemented. In addition, hand-searching of references cited in each publication as well as the bibliography of relevant systematic review articles was performed.

Study records

Study selection and data extraction

The search output (5416 studies) was imported into EppiReviewer4(EPPI-Centre 2020) and accurately controlled for duplicates. After 1549 duplicates had been removed, 3867 studies were double-screed (double screening performed by M. Basso and P. Knytl in consultation with K. Cohen Kadosh when disagreement occurred) for titles and abstract- among them, 3827 were excluded for population and outcome, whereas 4 due to text unavailability. 36 full-text studies were then double-assessed for eligibility- 21 were excluded for population and outcome while 1 was excluded as highly likely to have assessed the same sample cohorts of other two included studies (Kato-Kataoka, Nishida, Takada, Kawai, et al., 2016; Kato-Kataoka, Nishida, Takada, Suda, et al., 2016). The final output for the systematic review was 14 studies, among which 10 were included in the meta-analyses.

27

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

Excel tables were used to support the qualitative data extraction process (performed by M.Basso an P.Knytl), whereas Review Manager 5 was used to extract the quantitative data. When the research report did not provide all the data needed, authors were contacted via e-mail.

Risk of bias assessment

In regard with anxiety studies, the risk of bias (RoB) assessment was done at outcome level, whereas the RoB of studies measuring stress was assessed at study level. Based on the Revised Cochrane risk-of-bias tool for randomization trials (RoB-2),(Sterne, Savovic et al. 2019) the following bias domains were considered:

- Random sequence generation (selection bias)
- Allocation concealment (selection bias)
- Personnel and participant blinding (performance bias)
- Outcome assessment blinding (detection bias)
- Incomplete outcome data (attrition bias)
- Selective reporting (reporting bias)
- Other sources of bias

Statistical analyses

Data were extracted as standardized mean differences (SMDs) with 95% CI and I² statistics was used as a between-studies heterogeneity index (Higgins, Thompson et al. 2003). The pooled SMD was calculated based on a random-effects model using Review Manager 5. Sensitivity analyses were also performed removing the studies at high risk of bias from the analyses.

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

Appendix 2: search terms

PUBMED: 449 results

#1 humans[MeSH Terms] OR patients[MeSH Terms] OR research subjects[MeSH Terms] OR human experimentation[MeSH Terms] OR human*[title/abstract] OR client*[title/abstract] OR individual*[title/abstract] OR subject*[title/abstract] OR participant* [title/abstract]

#2 minors[MeSH Terms] OR adolescent[MeSH Terms] OR child[MeSH Terms] OR adolescence[MeSH Terms] OR adolescent, development[MeSH Terms] OR child, development[MeSH Terms] OR paediatric[MeSH Terms] OR puberty[Mesh Terms] OR young adult[sMeSH Terms] OR teen*[title/abstract] OR young men[title/abstract] OR young women[title/abstract] OR adolescen*[title/abstract] OR youth [title/abstract] OR undergraduate student* [title/abstract] OR college student* [title/abstract]

#3 prebiotics[MeSH Terms] OR probiotics[MeSH Terms] OR dietary carbohydrates[Mesh Terms OR dietary fiber[MeSH Terms] OR psychobiotic*[title/abstract] OR probio*[title/abstract] OR prebio*[title/abstract] OR pro-bio*[title/abstract] OR pre-bio*[title/abstract] OR lactobacill* [title/abstract] OR bifidobacteri*[title/abstract]

#4 anxiety[MeSH Terms] OR anxiety disorders[MeSH Terms] OR test anxiety scale[MeSH Terms] OR manifest anxiety scale[MeSH Terms] OR patient health questionnaire[MeSH Terms] OR survey and questionnaire/psychology[MeSH Terms] OR psychology, child[MeSH Terms] OR psychology, adolescent[MeSH Terms] OR child behavior disorders[MeSH Terms] OR panic[MeSH Terms] OR affect[Mesh Terms] OR affect[Mesh Terms] OR affective symptoms[MeSH Terms] OR performance anxiety[MeSH Terms] OR stress, psychological[MeSH Terms] OR anxi*[title/abstract] OR stress[Text Word] OR PSS[Text Word] OR SAS[Text Word] OR DASS[Text Word] OR HADS[Text Word] OR BAI[Text Word] OR STAI[Text Word] OR PHQ[Text Word] OR Emotional decision*[text word] OR psychological distress [mesh terms] OR emotions[mesh Terms] OR emotion [mesh terms] OR "emotional stroop" [text word] OR "dot probe[text word]

COCHRANE: 372 results

#1 [mh humans] OR [mh patients] or [mh "research subjects"] OR [mh "human experimentation"] OR participant OR client OR individual OR subject

#2 [mh minors] OR [mh adolescent] OR [mh adolescence] OR [mh child] or [mh puberty] or [mh "adolescent, development"] or [mh "child, development"] OR [mh paediatric] or "young men" or "young women" or teen* or adolescen* or "undergraduate student" or "college student"

#3 [mh probiotics] or [mh prebiotics] or psychobiotic* or probio* or prebio* or [mh "dietary carbohydrates"] or [mh "dietary fiber"] or bifidobacteri* or lactobacill*

#4 [mh anxiety] or [mh "anxiety disorders"] or [mh affect] or [mh panic] or [mh "affective symptoms"] or [mh "patient health questionnaire"] or [mh "survey and questionnaires"/PX] or [mh "psychology, child"] or [mh "psychology, adolescent"] or [mh "test anxiety scale"] or [mh "manifest anxiety scale"] or [mh "child behavior disorders"] or [mh "performance anxiety"] or [mh "stress, psychological"] or [mh "emotion regulation"] or [mh emotions] or [mh "psychological distress"] or anxi* or sas or dass or hads or had-s or stai or bai or phq or pss or "emotional stroop" or "dotprobe" medRxiv preprint doi: https://doi.org/10.1101/2020.11.09.20228445; this version posted December 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

#1 (MM "Humans") OR (MH "Patients+") OR (MH "Research Subjects+") OR (MH "Human Experimentation+") OR "human*" OR "subject*" OR "individual* OR "client*" OR participant*

#2 (MM "Minors") OR (MM "Adolescent") OR (MM "Adolescent Development") OR (MH "Child+") OR (MH "Child Development+") OR "adolescen*" OR (MH "Pediatrics") OR (MM "Puberty") OR (MM "Young Adult") OR "teen*" OR "youth" OR "young men" OR "young women" or "undergraduate student" or "college student"

#3 (MM "Probiotics") OR (MM "Prebiotics") OR (MM "Dietary Carbohydrates") OR (MM "Dietary Fiber") OR "psychobiotic*" OR "probio* OR "prebio*" OR "pro-bio*" OR "pre-bio*" OR "lactobacill*" OR "bifidobacteri*"

#4 (MH "Anxiety+") OR (MH "Anxiety Disorders+") OR (MM "Test Anxiety Scale") OR (MM "Manifest Anxiety Scale") OR (MM "Patient Health Questionnaire") OR (MM "Surveys and Questionnaires"/PX) OR (MM "Psychology, Child") OR (MM "Psychology, Adolescent") OR (MM "Child Behavior Disorders") OR (MM "Panic") OR (MH "Affect+") OR (MH "Affective Symptoms+") OR (MM "Performance Anxiety") OR (MH "Stress, Psychological+") OR (MH "Emotions+") OR (MH "Psychological Distress") OR (MM "Emotional Regulation") OR "SAS" OR "DASS" OR "HADS" OR "HADS" OR "HAD-S" OR "BAI" OR "STAI" OR "PHQ" OR "PSS" OR "anxi*" OR "emotional stroop" OR "Emotional decision*" OR "dot probe" OR "stress"

SCOPUS:2071 results

((TITLE-ABS-KEY(human) OR TITLE-ABS-KEY(patient) OR TITLE-ABS-KEY("research subject") OR TITLE-ABS-KEY("human trial") OR TITLE-ABS-KEY(subject) OR TITLE-ABS-KEY(client) OR TITLE-ABS-KEY(individual))) and ((TITLE-ABS-KEY(minor) OR TITLE-ABS-KEY(adolescen*) OR TITLE-ABS-KEY(child) OR TITLE-ABS-KEY("young adult") OR TITLE-ABS-KEY(teen*) OR TITLE-ABS-KEY("young m?n") OR TITLE-ABS-KEY("young wom?n") OR TITLE-ABS-KEY(youth) OR TITLE-ABS-KEY("undergraduate student*") OR TITLE-ABS-KEY("college student*"))) and ((TITLE-ABS-KEY(prebiotic) OR TITLE-ABS-KEY(probiotic) OR TITLE-ABS-KEY(psychobiotic) OR TITLE-ABS-KEY(lactobacill*) OR TITLE-ABS-KEY(probiotic) OR TITLE-ABS-KEY("dietary fiber"))) and ((TITLE-ABS-KEY(anxi*) OR TITLE-ABS-KEY(affect*) OR TITLE-ABS-KEY("emotion regulation") OR TITLE-ABS-KEY(emotional disorder") OR TITLE-ABS-KEY("patient health questionnaire") OR TITLE-ABS-KEY(panic) OR TITLE-ABS-KEY(psychologic*) OR TITLE-ABS-KEY(sas) OR TITLE-ABS-KEY(dass) OR TITLE-ABS-KEY(had?s) OR TITLE-ABS-KEY(bai) OR TITLE-ABS-KEY(stai) OR TITLE-ABS-KEY(psy OR TITLE-ABS-KEY(bai) OR TITLE-ABS-KEY(stai) OR TITLE-ABS-KEY(psy OR TITLE-ABS-KEY(phq) OR TITLE-ABS-KEY(sas) OR TITLE-ABS-KEY(anxi*) OR TITLE-ABS-KEY(had?s) OR TITLE-ABS-KEY(bai) OR TITLE-ABS-KEY(stai) OR TITLE-ABS-KEY("stress) OR TITLE-ABS-KEY(stress)))

EMBASE: 347 results

#1 'human'/exp OR 'patient'/exp OR 'research subject'/exp OR 'human experiment'/exp OR human*:ti,ab OR client*:ti,ab OR individual*:ti,ab OR subject*:ti,ab OR participant*:ti,ab

#2 'minor'/exp OR 'adolescent'/exp OR 'child'/exp OR 'adolescence'/exp OR 'young adult'/exp OR 'young m#n':ti,ab OR 'young wom#n':ti,ab OR teen*:ti,ab OR adolescen*:ti,ab OR youth:ti,ab or 'undergraduate student*':ti,ab or 'college student*':ti,ab

#3 'probiotic agent'/exp OR 'prebiotic agent'/exp OR 'dietary fiber'/exp OR 'psychobiotic agent'/exp OR 'lactobacillus'/exp OR 'bifidobacterium'/exp OR psychobiotic*:ti,ab OR pro?bio*:ti,ab OR pre?bio*:ti,ab OR lactobacill*:ti,ab OR bifidofacteri*:ti,ab

#4 'anxiety'/exp OR 'anxiety disorder'/exp OR 'anxiety psychology'/exp OR 'anxiety assessment'/exp OR 'child psychology'/exp OR 'affect'/exp OR 'emotion regulation'/exp OR

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

'emotional disorder'/exp OR 'emotional stress'/exp OR 'patient health questionnaire'/exp OR 'behavior/psychological aspect' OR sas:ti,ab OR dass:ti,ab OR had?s:ti,ab OR bai:ti,ab OR stai:ti,ab OR phq:ti,ab OR pss:ti,ab OR anxi*:ti,ab OR 'emotional stroop':ti,ab OR 'dot?probe':ti,ab OR distress:ti,ab OR stress:ti,ab OR 'emotional decision*':ti,ab

PSYCHINFO: 33 results

#1 DE "Experimental Subjects" OR AB participant* OR TABsubject* OR AB individual* OR AB human*

#2 DE "Adolescent Psychopathology" OR DE "Adolescent Psychology" OR DE "Adolescent Psychiatry" OR DE "Adolescent Development" OR DE "Adolescent Behavior" OR DE "Adolescent Characteristics" OR DE "Adolescent Health" OR DE "Early Adolescence" OR AB child* OR AB adolescen* OR AB teen* OR AB youth OR AB "young adult*" OR AB "young women" OR AB "young men" or AB"undergraduate student*" or AB"college student*"

#3 DE "Dietary Supplements" OR AB probio* OR AB prebio* OR AB lactobacill* OR AB bifidobacteri* OR AB psychobiotic* OR AB "dietary fiber*"

#4 (((((((((((((((((((((((((((() a Nxiety OR DE "Anxiety Sensitivity" OR DE "Computer Anxiety" OR DE "Health Anxiety" OR DE "Mathematics Anxiety" OR DE "Performance Anxiety" OR DE "Social Anxiety" OR DE "Speech Anxiety" OR DE "Test Anxiety" OR DE "Anxiety Disorders" OR DE "Castration Anxiety" OR DE "Death Anxiety" OR DE "Generalized Anxiety Disorder" OR DE "Obsessive Compulsive Disorder" OR DE "Panic Attack" OR DE "Panic Disorder" OR DE "Phobias" OR DE "Separation Anxiety Disorder" OR DE "Trichotillomania" OR DE "Taylor Manifest Anxiety Scale" OR DE "State Trait Anxiety Inventory" OR DE "Childrens Manifest Anxiety Scale") OR (DE "Child Behavior Checklist")) OR (DE "Mental Health and Illness Assessment")) OR (DE "Health Psychology Assessment" OR DE "Health Attitude Measures" OR DE "Health Behavior Measures"))) OR (DE "Psychodiagnostic Measures")) OR (DE "Psychodiagnostic Interview" OR DE "Diagnostic Interview Schedule" OR DE "Structured Clinical Interview")) OR (DE "Attentional Bias")) OR (DE "Behavioral Assessment")) OR (DE "Distress") OR AB "emotion regulation" OR TX "emotional stroop" OR TX "dot probe" OR TX SAS OR TX DASS OR TX DA?S OR TX BAI OR TX STAI OR TX PHQ OR TX PSS

WEB OF SCIENCE: 2029 results

#1 TOPIC (human* OR patient* OR subject* OR client* OR individual*)

#2 TOPIC (adolescen* OR child* OR "young adult*"OR teen* OR "young m?n" OR "young wom?n" OR youth or "undergraduate student*" or "college student*")

#3 TOPIC (prebiotic* OR probiotic* OR psychobiotic*OR lactobacill* OR bifidobacter*OR "dietary fiber*")

#4 TOPIC (anxi* OR affect*OR "emotion* regulation" OR "emotional disorder* OR "patient health questionnaire" OR sas OR dass OR had?s OR stai OR bai OR phq OR pss OR panicOR "emotional stroop"OR " dot?probe" OR "psychological distress" OR stress)

Appendix 3: Risk of Bias Assessment of anxiety studies

Unique ID	K20STAIS	Study ID	Kar20	Assessor	
Ref or Label	Karbownik 2020	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	Probiotic	Comparat or	placebo	Source	
Outcome	STAI state	Results	-0,04	Weight	19.9
Domain	Signalling question	1		Response	Comments
Bias arising	1.1 Was the allocatior	n sequence ra	andom?	Y	
from the randomiz ation	1.2 Was the allocation participants were enror interventions?	•		Y	
process	1.3 Did baseline differ groups suggest a prob process?		N		
	Risk of bias judgemer	nt	Low		
Bias due to	2.1.Were participants intervention during th	eir assigned	N		
deviation s from intended	2.2.Were carers and p aware of participants' trial?	•	-	N	
interventi ons	2.3. If Y/PY/NI to 2.1 c the intended interven experimental context	tion that aro	PN		
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?				
	2.5. If Y/PY/NI to 2.4: intended intervention		NA		
	2.6 Was an appropriat effect of assignment t	•	PY		
	2.7 If N/PN/NI to 2.6: substantial impact (or analyse participants ir randomized?	the result) o	of the failure to	PN	
	Risk of bias judgement				
Bias due to	3.1 Were data for this nearly all, participants			N	

					·
missing outcome data	3.2 If N/PN/NI to 3.1: not biased by missing			PY	ITT analysis did not show different statistical results in comparison to PP analysis
	3.3 If N/PN to 3.2: Cou depend on its true val	-	ess in the outcome	NA	
	3.4 If Y/PY/NI to 3.3: Is outcome depended of		-	NA	
	Risk of bias judgemer	nt		Low	
Bias in measure	4.1 Was the method c inappropriate?	of measuring	the outcome	N	
ment of the	4.2 Could measureme outcome have differed			N	
outcome	4.3 Were outcome ass received by study part		e of the intervention	N	
	4.4 If Y/PY/NI to 4.3: C have been influenced received?			NA	
	4.5 If Y/PY/NI to 4.4: Is outcome was influenc received?			NA	
	Risk of bias judgemer	nt		Low	
Bias in selection of the reported	5.1 Were the data tha accordance with a pre finalized before unblir for analysis?	e-specified ar	-	NI	
result	5.2 multiple eligible scales, definitions, tim domain?			NI	
	5.3 multiple eligible	analyses of	the data?	NI	
	Risk of bias judgemer	nt		Some concerns	
Overall bias	Risk of bias judgemer	nt		Some concerns	
Unique ID	K09STAITOT	Study ID	Kit09	Assessor	
Ref or Label	Kitaoka 2009	Aim	assignment to intervention (the 'intention-to-treat' effect)		

Cohen Kadosh et al. WT Active Ingredients: Better Gut Microbiome Function Final Report

Experime	prebiotic	Comparat	placebo	Source	
ntal	prebiotic	or	placebo	Source	
Outcome	STAI-total	Results	0,6	Weight	2.8
Domain	Signalling question			Response	Comments
Bias	1.1 Was the allocation	NI			
arising from the				-	
randomiz	1.2 Was the allocation participants were enro	NI			
ation	interventions?				
process	1.3 Did baseline differ			PY	prebiotic group:
	groups suggest a prob	lem with the	randomization		100.5 at baseline
	process?				down to 93.63 at t2 (with p<0.05)
					(with p (0.05)
					placebo group:
			87.73 at baseline		
	Risk of bias judgemen	High	down to 84.25		
	hisk of blas judgemen				
Bias due	2.1.Were participants	aware of the	eir assigned	N	
to	intervention during th	e trial?			
deviation s from	2.2.Were carers and p	•	-	Ν	
intended	aware of participants' trial?	assigned inte	ervention during the		
interventi	2.3. If Y/PY/NI to 2.1 c	or 2.2: Were t	there deviations from	NI	
ons	the intended interven		se because of the		
	experimental context				
	2.4 If Y/PY to 2.3: Wer affected the outcome		ations likely to have	NA	
	2.5. If Y/PY/NI to 2.4: 1	Were these c	leviations from	NA	
	intended intervention	balanced be	tween groups?		
	2.6 Was an appropriat	•		NI	
	effect of assignment t				
	2.7 If N/PN/NI to 2.6:	NI			
	substantial impact (or analyse participants ir				
	randomized?				
	Risk of bias judgemen	it		High	The authors did not
					include a participant flow diagram or any
				relevant information	
				about adherence to	
				intervention or	
Bias due	3.1 Were data for this	outcome av	ailable for all or	NI	protocol deviations
to	nearly all, participants				

missing	3.2 If N/PN/NI to 3.1: Is there evidence that result was	PN	
missing outcome	not biased by missing outcome data?	PN	
data	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NI	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NI	
	Risk of bias judgement	High	Again, authors did not provide a flow diagram, or give detailed information about participants who entered the studies, lost to follow-up, withdrawn, etc.
Bias in measure	4.1 Was the method of measuring the outcome inappropriate?	N	
ment of the	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
outcome	4.3 Were outcome assessors aware of the intervention received by study participants?	N	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	NA	
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	
	Risk of bias judgement	Low	
Bias in selection of the reported	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	
result	5.2 multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	NI	
	5.3 multiple eligible analyses of the data?	NI	
	Risk of bias judgement	Some concerns	

• "				1	
Overall bias	Risk of bias judgeme	nt		High	The authors did not give enough information about the randomization and allocation process. Anxiety scores of the two groups differed at baseline, possibly biasing the comparison between group at t2 as no baseline correction has been carried out. Indeed, significant decrease in anxiety scores was found in the prebiotic group (<0,05) only, but the comparison between placebo and experimental group means at t2 does not reflect such effect (d=0,6). Finally, the authors did not provide a participant flow diagram or information about adherence and missing data.
Unique	K11BAI	Study ID	Kie11	Assessor	
ID Ref or Label	Kiecolt-Glaser 2011	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	prebiotic	Comparat or	placebo	Source	Non-commercial trial registry record (e.g. ClinicalTrials.gov record)
Outcome	BAI	Results	-0,61	Weight	10.6

Domain	Signalling question	Response	Comments
Bias arising	1.1 Was the allocation sequence random?	Y	
from the randomiz ation	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	Y	
process	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?	PN	
	Risk of bias judgement	Low	
Bias due to	2.1.Were participants aware of their assigned intervention during the trial?	N	
deviation s from intended	2.2.Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	N	
interventi ons	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?	NA	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	Y	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	Risk of bias judgement	Low	
Bias due to	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Y	
missing outcome data	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
Jala	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	Risk of bias judgement	Low	
Bias in measure	4.1 Was the method of measuring the outcome inappropriate?	N	
ment of the outcome	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
outcome	4.3 Were outcome assessors aware of the intervention received by study participants?	N	

	4.4 If Y/PY/NI to 4.3: (have been influenced received?			NA	
	4.5 If Y/PY/NI to 4.4: I outcome was influence received?	•	NA		
	Risk of bias judgemen	nt	Low		
Bias in selection of the reported result	5.1 Were the data tha accordance with a pre finalized before unblin for analysis?	e-specified an nded outcom	NI	The trial protocol pre-specifies how the outcomes will be treated but not how statistically analysed	
	5.2 multiple eligible scales, definitions, tin domain?	N			
	5.3 multiple eligible	e analyses of	the data?	N	
	Risk of bias judgemen	nt	Low	In the paper authors mentioned pre- planned analysis to be in line with the performed analysis.	
Overall bias	Risk of bias judgemen	nt	Low		
Unique ID	L188CBCL	Study ID	Liu19	Assessor	
Ref or Label	Liu 2019	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	probiotic	Comparat or	placebo	Source	Non-commercial trial registry record (e.g. ClinicalTrials.gov record)
Outcome	CBCL	Results	-0,05	Weight	11.4
Domain	Signalling question			Response	Comments
Bias arising	1.1 Was the allocation	n sequence ra	andom?	Y	
from the randomiz	1.2 Was the allocation participants were enr interventions?			Y	

ort			

ation	1.3 Did baseline differences between intervention	N	
ation process	groups suggest a problem with the randomization	N	
	process? Risk of bias judgement	Low	
Bias due to	2.1.Were participants aware of their assigned intervention during the trial?	N	
deviation s from intended	2.2.Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	N	
interventi ons	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?	N	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	N	Participants who discontinued the intervention were excluded from the analysis
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	PN	
	Risk of bias judgement	Some concerns	
Bias due to	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	N	
missing outcome	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	N	
data	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	PN	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	Risk of bias judgement	Low	
Bias in measure	4.1 Was the method of measuring the outcome inappropriate?	N	
ment of the outcome	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
Jucome	4.3 Were outcome assessors aware of the intervention received by study participants?	N	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	NA	

	4.5 If Y/PY/NI to 4.4: I			NA	
	outcome was influent received?	ed by knowle	edge of intervention		
	Risk of bias judgemen	nt		Low	
Bias in selection of the reported	5.1 Were the data that accordance with a pre- finalized before unblin for analysis?	e-specified ar	•	NI	Tn the trial protocol there is no pre- specified analysis information
result	5.2 multiple eligible scales, definitions, tin domain?		N		
	5.3 multiple eligible	analyses of	the data?	NI	
	Risk of bias judgemen	nt		Some concerns	
Overall bias	Risk of bias judgemen	nt	Some concerns		
Unique	M18BAIT	Study ID	Man18	Assessor	
ID	IVIIODALI	Study ID	IVId1110	Assessor	
Ref or Label	Manos 2018	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	prebiotic	Comparat or	placebo	Source	
Outcome	BAIT	Results	1,08	Weight	2.8
Domain	Signalling question			Response	Comments
Bias arising	1.1 Was the allocation	n sequence ra	andom?	Y	
from the randomiz ation	1.2 Was the allocation sequence concealed until			Y	
process				PY	Mean trait anxiety scores are higher in the omega-3 PUFA group (severe anxiety) compared to the placebo group (moderate anxiety)
	Risk of bias judgemen	nt		Some concerns	

Bias due to	2.1.Were participants aware of their assigned intervention during the trial?	N	
deviation s from intended	2.2.Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	N	
interventi ons	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?	NA	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	Y	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	Risk of bias judgement	Low	
Bias due to	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	N	
missing outcome data	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	N	
Gala	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NI	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	PN	
	Risk of bias judgement	Some concerns	
Bias in measure ment of the outcome	4.1 Was the method of measuring the outcome inappropriate?	PY	State anxiety should have been measured as well, as more sensible to potential transient reactions related to the intervention
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	NA	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	NA	
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	
	Risk of bias judgement	High	

Bias in	5.1 Were the data t	nat produced t	his result analysed in	NI	
selection	accordance with a p	re-specified ar	alysis plan that was		
of the	•	•	e data were available		
reported	for analysis?				
result	5.2 multiple eligit	le outcome m	essurements (e.g.	NI	
resure					
	scales, definitions, t domain?	me points) wi	inin the outcome		
	5.3 multiple eligit	le analyses of	the data?	NI	
	Risk of bias judgem	ent		Some	
				concerns	
Overall	Dick of bias judgom			Llich	
	Risk of bias judgem	ent		High	
bias			-		
				+	
Unique	M04STAIS	Study ID	Marco04	Assessor	
ID					
Ref or	Marcos 2004	Aim	assignment to		
Label			intervention (the		
Label			'intention-to-treat'		
			effect)		
Experime	probiotic	Comparat	placebo	Source	
ntal	p	or			
		-	0.24	Maisht	10.0
Outcome	STAI-state	Results	-0,24	Weight	18.6
Domain	Signalling question			Response	Comments
Bias	1.1 Was the allocation	on sequence ra	andom?	NI	
arising	1.1 Was the anotati	Shi Sequence h			
from the					-
	1.2 Was the allocation	•		NI	
randomiz	participants were er	rolled and ass	igned to		
ation	interventions?				
process	1.3 Did baseline diff	erences betwe	en intervention	N	
	groups suggest a pro	blem with the	e randomization		
	process?				
	Risk of bias judgem	ent		Some	
	nisk of blas judgeth			concerns	
D: 1					
Bias due	2.1.Were participan		eir assigned	PY	The study design is
to	intervention during	the trial?			not described as
deviation	2.2.Were carers and	people delive	ring the interventions	PY	blinded/double
s from		• •	ervention during the		blinded.
intended	trial?	s assigned int	ci tendon during the		
interventi		or 2 2.14/	have doubtiers from	N	
ons			there deviations from	Ν	
0.10	the intended intervention that arose because of the			1	
	experimental contex				

r		
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	NI
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NI
	Risk of bias judgement	High
Bias due to	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	N
missing outcome	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	N
data	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	PN
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA
	Risk of bias judgement	Low
Bias in measure	4.1 Was the method of measuring the outcome inappropriate?	N
ment of the	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N
outcome	4.3 Were outcome assessors aware of the intervention received by study participants?	РҮ
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	РҮ
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN
	Risk of bias judgement	Some concerns
Bias in selection of the reported	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI
result	5.2 multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	NI
	5.3 multiple eligible analyses of the data?	NI
	Risk of bias judgement	Some concerns

Overall bias	Risk of bias judgement			High	Controlled parallel group design, not placebo-controlled, not double-blinded.
Unique ID	M04STAIT	Study ID	Marco04	Assessor	
Ref or Label	Marcos 2004	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	probiotic	Comparat or	placebo	Source	
Outcome	STAI trait	Results	-0,03	Weight	0
Domain	Signalling question		I	Response	Comments
Bias arising	1.1 Was the allocation	on sequence ra	andom?	NI	
from the randomiz ation	1.2 Was the allocatic participants were en interventions?		NI		
process	1.3 Did baseline diffe groups suggest a pro process?			N	
	Risk of bias judgeme	ent	Some concerns		
Bias due to	2.1.Were participant intervention during t		eir assigned	РҮ	
deviation s from intended	2.2.Were carers and aware of participants trial?	s' assigned inte	РҮ		
interventi ons	2.3. If Y/PY/NI to 2.1 the intended interve experimental contex	ntion that aro t?	N		
	2.4 If Y/PY to 2.3: We affected the outcom		NA		
	2.5. If Y/PY/NI to 2.4 intended interventio		NA		
	2.6 Was an appropria effect of assignment			NI	
	2.7 If N/PN/NI to 2.6 substantial impact (c analyse participants randomized?	on the result) o	NI		

	Risk of bias judgemer	nt		High	
Bias due	3.1 Were data for this		N		
to missing	nearly all, participants				
missing outcome	3.2 If N/PN/NI to 3.1:			Ν	
data	not biased by missing				
	3.3 If N/PN to 3.2: Cou depend on its true val	-	PN		
	3.4 If Y/PY/NI to 3.3: I	s it likely tha	t missingness in the	NA	
	outcome depended o	n its true val			
	Risk of bias judgemer	nt	Low		
Bias in	4.1 Was the method o	of measuring	the outcome	N	
measure	inappropriate?				
ment of the	4.2 Could measureme outcome have differe			N	
outcome	4.3 Were outcome as received by study par		e of the intervention	РҮ	
	4.4 If Y/PY/NI to 4.3: 0 have been influenced received?		PY		
	4.5 If Y/PY/NI to 4.4: I outcome was influenc received?	•	PN		
	Risk of bias judgemer	nt	Some concerns		
Bias in	5.1 Were the data tha	t produced t	this result analysed in	NI	
selection	accordance with a pre		-		
of the	-	•	ne data were available		
reported	for analysis?				
result	5.2 multiple eligible scales, definitions, tim domain?			NI	
	5.3 multiple eligible	e analyses of	NI		
	Risk of bias judgemer	nt		Some concerns	
Overall bias	Risk of bias judgemer	nt		High	
Unique ID	S14STAISF	Study ID	Sch14	Assessor	
	Calanaialt	Aim	assignment to	1	
Ref or	Schmidt				

			'intention-to-treat'		
			effect)		
			enect)		
Experime ntal	prebiotic FOS	Comparat or	placebo	Source	Non-commercial trial registry record (e.g. ClinicalTrials.gov record)
Outcome	STAI-state	Results	-0,02	Weight	5.4
Domain	Signalling question	I		Response	Comments
Bias arising	1.1 Was the allocatior	sequence ra	andom?	NI	
from the randomiz ation	1.2 Was the allocation participants were enror interventions?	•		NI	
process					
	Risk of bias judgemer	it	Some concerns		
Bias due to	2.1.Were participants intervention during th		eir assigned	N	
deviation s from intended	2.2.Were carers and p aware of participants' trial?	•	-	N	
interventi ons	2.3. If Y/PY/NI to 2.1 c the intended interven experimental context	tion that aro		NI	
	2.4 If Y/PY to 2.3: Wer affected the outcome		NA		
	2.5. If Y/PY/NI to 2.4: intended intervention		NA		
	2.6 Was an appropriat effect of assignment t	o interventio	N		
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?			N	
	Risk of bias judgemer	nt		Some concerns	
Bias due to missing outcome data	3.1 Were data for this nearly all, participants			N	Data were available for 93,75% of the participants (to be sufficient it should be 95% based on the Risk of Bias tool assessment RoB2.0)

	3.2 If N/PN/NI to 3.1: not biased by missing			N	No sensitivity analysis was performed
	3.3 If N/PN to 3.2: Cou depend on its true val	NI	Reasons for drop- out are not reported		
	3.4 If Y/PY/NI to 3.3: Is outcome depended or		-	PN	
	Risk of bias judgemen	ıt		Some concerns	
Bias in measure	4.1 Was the method o inappropriate?	of measuring	the outcome	N	
ment of the outcome	4.2 Could measureme outcome have differed			N	
outcome	4.3 Were outcome ass received by study part		e of the intervention	N	
	4.4 If Y/PY/NI to 4.3: C have been influenced received?			NA	
	4.5 If Y/PY/NI to 4.4: Is outcome was influenc received?			NA	
	Risk of bias judgemen	it		Low	
Bias in selection of the reported	5.1 Were the data tha accordance with a pre finalized before unblir for analysis?	-specified an	alysis plan that was	NI	
result	5.2 multiple eligible scales, definitions, tim domain?			NI	In the trial protocol authors do not mention any self- reported anxiety outcome
	5.3 multiple eligible	analyses of t	he data?	NI	SAP are not reported
	Risk of bias judgemen	ıt		Some concerns	
				conteerns	
Overall bias	Risk of bias judgemen	ıt		Some concerns	Overall good quality but some relevant information in regards with the study design are not reported, reason for missing data neither, and a statistical analysis plan is not available

Unique ID	S14STAISBG	Study ID	Sch14	Assessor	
Ref or Label	Schmidt 2014	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	prebiotic B-GOS	Comparat or	placebo	Source	Non-commercial trial registry record (e.g. ClinicalTrials.gov record)
Outcome	STAI-state	Results	0,01	Weight	5.4
Domain	Signalling question		Response	Comments	
Bias arising	1.1 Was the allocation	on sequence ra	NI		
from the randomiz ation	1.2 Was the allocation participants were en interventions?	•	NI]	
process	1.3 Did baseline diffe groups suggest a pro process?		N		
	Risk of bias judgeme	ent	Some concerns		
Bias due to	2.1.Were participant intervention during		eir assigned	N	
deviation s from intended	2.2.Were carers and aware of participant trial?		N		
interventi ons	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			NI	
	2.4 If Y/PY to 2.3: We affected the outcom		NA		
	2.5. If Y/PY/NI to 2.4 intended intervention		NA		
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?			N	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?			N	
	Risk of bias judgeme	ent	Some concerns		
Bias due to	3.1 Were data for th nearly all, participan			N	

				1	
missing	3.2 If N/PN/NI to 3.1:			Ν	
outcome	not biased by missing	outcome dat	:a?		
data	3.3 If N/PN to 3.2: Co depend on its true va	-	NI		
	3.4 If Y/PY/NI to 3.3: I outcome depended o	•	PN		
	Risk of bias judgemen			Some	
				concerns	
Bias in	4.1 Was the method of	of measuring	the outcome	N	
measure	inappropriate?	-			
ment of	4.2 Could measureme	ent or ascerta	inment of the	N	
the	outcome have differe	d between in	tervention groups?		
outcome	4.3 Were outcome as	sessors aware	e of the intervention	N	
	received by study par	ticipants?			
	4.4 If Y/PY/NI to 4.3: 0	Could assessn	nent of the outcome	NA	
	have been influenced	by knowledg	e of intervention		
	received?				
	4.5 If Y/PY/NI to 4.4: I outcome was influence	•		NA	
	received?				
	Risk of bias judgemen	nt		Low	
Bias in	5.1 Were the data tha	t produced t	his result analysed in	NI	
selection	accordance with a pre	•			
of the	finalized before unblin	nded outcom	e data were available		
reported	for analysis?		acuramante la g	NU	
result	5.2 multiple eligible scales, definitions, tin			NI	
	domain?				
	5.3 multiple eligible	e analyses of	the data?	NI	
	Risk of bias judgemen	nt		Some	
				concerns	
Overall	Risk of bias judgemen	nt		Some	
bias		1	I	concerns	
				+	
Unique	TAODAID	Study ID	Tra19	Assessor	
ID	ΓΓΥΚΔΙΡ	Judy ID		A33C3301	
Ref or	T19BAIP				
Label	Tran 2019	Aim	assignment to		
		Aim	assignment to intervention (the		
		Aim	intervention (the 'intention-to-treat'		
		Aim	intervention (the		
Experime		Aim	intervention (the 'intention-to-treat'	Source	
	Tran 2019		intervention (the 'intention-to-treat' effect)		

Outcome	BAI all conditions	Results	4/ 4.2/ 4.4/ 4.3	Weight	16.9
Domain	Signalling question	I		Response	Comments
Bias arising	1.1 Was the allocation	sequence ra	andom?	РҮ	Randomization performed in Excel.
from the randomiz ation process	1.2 Was the allocation participants were enro interventions?	•	NI	No detailed info about allocation methods, just stated that the leader investigator (not in direct contact with subjects) was aware of the assigned intervention	
	1.3 Did baseline differ groups suggest a prob process?		N		
	Risk of bias judgemen	it	Some concerns		
Bias due to	2.1.Were participants intervention during th		N		
deviation s from intended	2.2.Were carers and p aware of participants' trial?	•	N		
interventi ons	2.3. If Y/PY/NI to 2.1 o the intended interven experimental context	tion that aro	NI		
	2.4 If Y/PY to 2.3: Wer affected the outcome	e these devi	NA		
	2.5. If Y/PY/NI to 2.4: intended intervention		NA		
	2.6 Was an appropriat effect of assignment t	-	N	Participants who discontinued the intervention were not analysed	
	2.7 If N/PN/NI to 2.6: substantial impact (or analyse participants ir randomized?	the result) o	NI		
	Risk of bias judgemen	it	High		
Bias due to	3.1 Were data for this nearly all, participants		•	N	
missing outcome	3.2 If N/PN/NI to 3.1: not biased by missing			N	
data	3.3 If N/PN to 3.2: Cou depend on its true val	-	ess in the outcome	NI	

	3.4 If Y/PY/NI to 3.3: Is outcome depended of		-	PN	
	Risk of bias judgemer			Some concerns	
Bias in measure	4.1 Was the method c inappropriate?	of measuring	N		
ment of the outcome	4.2 Could measureme outcome have different		N		
outcome	4.3 Were outcome as received by study part		e of the intervention	N	
	4.4 If Y/PY/NI to 4.3: C have been influenced received?			NA	
	4.5 If Y/PY/NI to 4.4: Is outcome was influenc received?	•		NA	
	Risk of bias judgemer	nt	Low		
Bias in selection of the reported	ion accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available				
result	5.2 multiple eligible scales, definitions, tim domain?			NI	
	5.3 multiple eligible	analyses of	NI		
	Risk of bias judgemer	nt	Some concerns		
Overall bias	Risk of bias judgement			High	No enough information about the randomization and allocation process, no enough information about adherence to the intervention and reasons of missing data, no applied analysis to account for that, no trial protocol/SAP available.
Unique ID	K16STAIS	Study ID	Kat16	Assessor	

			· · · ·		1
Ref or Label	Kato-Kataoka 2016a	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	probiotic	Comparat or	placebo	Source	Company-owned trial registry record (e.g. GSK Clinical Study Register record)
Outcome	STAI-state	Results	-0.09	Weight	7.9
Domain	Signalling question	1		Response	Comments
Bias arising	1.1 Was the allocation	i sequence ra	andom?	PN	Authors never mention any
from the randomiz ation	1.2 Was the allocation participants were enr interventions?	•		NI	sequence randomization
process	1.3 Did baseline differ groups suggest a prot process?			N	
	Risk of bias judgemen	nt		Some concerns	
Bias due to	2.1.Were participants intervention during the second secon		N		
deviation s from intended	2.2.Were carers and p aware of participants trial?		N		
interventi ons	2.3. If Y/PY/NI to 2.1 of the intended interven experimental context	tion that aro	N		
	2.4 If Y/PY to 2.3: Wer affected the outcome	e these devia	NA		
	2.5. If Y/PY/NI to 2.4: intended intervention		NA		
	2.6 Was an appropria effect of assignment t	o interventio	Y	Post-allocation exclusion of participants who are no longer eligible independently from the group assignment (students who were not undergoing the final examination) can be considered appropriate	
	2.7 If N/PN/NI to 2.6: substantial impact (or	•		NA	

	analyse participants in the group to which they were randomized?		
	Risk of bias judgement	Low	
Bias due to missing outcome	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Ŷ	Participants that dropped out did so before starting the test beverages
data	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	Risk of bias judgement	Low	
Bias in measure	4.1 Was the method of measuring the outcome inappropriate?	N	
ment of the	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
outcome	4.3 Were outcome assessors aware of the intervention received by study participants?	N	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	NA	
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	
	Risk of bias judgement	Low	
Bias in selection of the reported	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	The trial registration record does not mention any of these details
result	5.2 multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	NI	
	5.3 multiple eligible analyses of the data?	NI	
	Risk of bias judgement	Some concerns	
Overall bias	Risk of bias judgement	Some concerns	

Unique	K16bSTAIS	Study ID	Kat16b	Assessor	
ID .					
Ref or Label	Kato-Kataoka 2016b	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	probiotic	Comparat or	placebo	Source	
Outcome	STAI-state	Results	0.21	Weight	8
Domain	Signalling question	1		Response	Comments
Bias arising	1.1 Was the allocation	•		N	It was based on the participants
from the randomiz ation	1.2 Was the allocation participants were enrol interventions?		NI	background data	
process				Y	STAI scores at baseline significantly differed between probiotic and placebo group (p<0,05)
	Risk of bias judgemer	nt		High	
Bias due to	2.1.Were participants intervention during th		eir assigned	N	
deviation s from intended	2.2.Were carers and p aware of participants' trial?	•	N		
interventi ons	2.3. If Y/PY/NI to 2.1 c the intended interven experimental context	tion that aro		N	
	2.4 If Y/PY to 2.3: Wer affected the outcome		NA		
	2.5. If Y/PY/NI to 2.4: intended intervention		NA		
	2.6 Was an appropriate of assignment t	•		Y	Post-allocation exclusion of participants who are no longer eligible independently from the group assignment (students who were not undergoing the final examination) can be considered appropriate

	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to	NA	
	analyse participants in the group to which they were		
	randomized?		
	Risk of bias judgement	Low	
Bias due	3.1 Were data for this outcome available for all, or	Ν	
to	nearly all, participants randomized?		
missing	3.2 If N/PN/NI to 3.1: Is there evidence that result was	Ν	
outcome data	not biased by missing outcome data?		
uata	3.3 If N/PN to 3.2: Could missingness in the outcome	Ν	Missing data comes
	depend on its true value?		from participants
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the	NA	excluded due to
	outcome depended on its true value?		failure in gaining enough credits to
			undergo the
			examination
	Risk of bias judgement	Low	
Bias in	4.1 Was the method of measuring the outcome	Ν	
measure	inappropriate?		
ment of	4.2 Could measurement or ascertainment of the	N	
the outcome	outcome have differed between intervention groups?		
outcome	4.3 Were outcome assessors aware of the intervention	Ν	
	received by study participants?		
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome	NA	
	have been influenced by knowledge of intervention		
	received? 4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the	NA	-
	outcome was influenced by knowledge of intervention	INA	
	received?		
	Risk of bias judgement	Low	
Bias in	5.1 Were the data that produced this result analysed in	NI	
selection	accordance with a pre-specified analysis plan that was		
of the	finalized before unblinded outcome data were available		
reported	for analysis?	NU	
result	5.2 multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome	NI	
	domain?		
	5.3 multiple eligible analyses of the data?	NI	
	Risk of bias judgement	Some	
		concerns	

Overall	Risk of bias judgement	High	There might have
bias			been some
			allocation problems
			or occurrence of
			confounding factors
			between the
			background data
			recording and
			baseline
			measurement as the
			STAI scores of the
			active group is
			significantly higher
			in respect with the
			placebo group at
			baseline.

APPENDIX 4: Risk of Bias Assessment of stress studies

Unique ID	A16	Study ID	And16	Assessor	
Ref or Label	Andersson (2016)	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	probiotic	Comparat or	placebo	Source	
Outcome	salivary cortisol and immunoglobulin A	Results		Weight	1
Domain	Signalling question	·		Response	Comments
Bias arising	1.1 Was the allocation	n sequence ra	NI		
from the randomiz ation	1.2 Was the allocation participants were enr interventions?	•		NI	
process	1.3 Did baseline differ groups suggest a prot process?			N	
	Risk of bias judgemer	nt	Some concerns		
Bias due to	2.1.Were participants aware of their assigned intervention during the trial?			N	
deviation s from intended	2.2.Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			N	
interventi ons	2.3. If Y/PY/NI to 2.1 of the intended interven experimental context	tion that aro		NA	

		1
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	NI
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	N
	Risk of bias judgement	Some concerns
Bias due to	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Y
missing outcome	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA
data	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA
	Risk of bias judgement	Low
Bias in measure	4.1 Was the method of measuring the outcome inappropriate?	N
ment of the	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N
outcome	4.3 Were outcome assessors aware of the intervention received by study participants?	N
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	NA
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA
	Risk of bias judgement	Low
Bias in selection of the reported	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI
result	5.2 multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	NI
	5.3 multiple eligible analyses of the data?	NI
	Risk of bias judgement	Some concerns

Overall bias	Risk of bias judgement			Some concerns	
Unique ID	C16	Study ID	Cul16	Assessor	
Ref or Label	Culpepper (2016)	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	probiotic	Comparat or	placebo	Source	
Outcome	self-reported stress	Results		Weight	1
Domain	Signalling question	1	I	Response	Comments
Bias arising	1.1 Was the allocation	n sequence ra	andom?	Y	
from the randomiz ation	1.2 Was the allocation participants were enr interventions?	•		PY	
process	1.3 Did baseline diffe groups suggest a prol process?			N	
	Risk of bias judgeme	nt	Low		
Bias due to	2.1.Were participants intervention during the		eir assigned	N	
deviation s from intended	2.2.Were carers and p aware of participants trial?	•	ring the interventions ervention during the	N	
interventi ons	2.3. If Y/PY/NI to 2.1 of the intended interver experimental context	ntion that aro	NA		
	2.4 If Y/PY to 2.3: We affected the outcome		NA		
	2.5. If Y/PY/NI to 2.4: intended intervention		NA		
	2.6 Was an appropria effect of assignment	•	Y		
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?			NA	
	Risk of bias judgeme	nt		Low	

	1			· ·	
Bias due	3.1 Were data for this		•	Y	
to	nearly all, participant	s randomized	52		
missing	3.2 If N/PN/NI to 3.1:			NA	
outcome data	not biased by missing	outcome da	ta?		
uata	3.3 If N/PN to 3.2: Co	-	ess in the outcome	NA	
	depend on its true va	lue?			
	3.4 If Y/PY/NI to 3.3: I	•	-	NA	
	outcome depended o	n its true val	ue?		
	Risk of bias judgeme	nt		Low	
Bias in	4.1 Was the method of	of measuring	the outcome	N	
measure	inappropriate?				
ment of	4.2 Could measureme	ent or ascerta	ainment of the	N	
the	outcome have differe				
outcome	4.3 Were outcome as			N	
	received by study par				
	4.4 If Y/PY/NI to 4.3:	•	ment of the outcome	NA	
	have been influenced			NA	
	received?	by knowieus			
	4.5 If Y/PY/NI to 4.4: I	s it likely tha	t assessment of the	NA	
	outcome was influence	•			
	received?	,	C		
	Risk of bias judgeme	nt		Low	
Bias in	5.1 Were the data tha	at produced t	this result analysed in	NI	
selection	accordance with a pro	•	•		
of the	finalized before unbli	nded outcom	ne data were available		
reported	for analysis?				
result	5.2 multiple eligible			NI	
	scales, definitions, tin	ne points) wi	thin the outcome		
	domain?		th - d-t-2		
	5.3 multiple eligible	e analyses of	the data?	NI	
	Risk of bias judgeme	nt		Some	
				concerns	
Overall	Risk of bias judgeme	nt		Some	
bias		-		concerns	
Unique	H11	Study ID	Hug11	Assessor	
ID		 • ·			
Ref or	Hughes (2011)	Aim	assignment to		
Label			intervention (the 'intention-to-treat'		
			effect)		
l					

Experime	prebiotics	Comparat	placebo	Source	
ntal	•	or			
Outcome	self-reported stress	Results		Weight	1
Domain	Signalling question			Response	Comments
Bias arising	1.1 Was the allocation sequence random?			Y	
from the randomiz ation	1.2 Was the allocation participants were enro interventions?	•		Y	-
process	1.3 Did baseline differ groups suggest a prob process?			PN	
	Risk of bias judgemer	nt		Low	
Bias due to	2.1.Were participants intervention during th		eir assigned	N	
deviation s from intended	2.2.Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			N	
interventi ons	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			NA	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?			NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?			PY	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?			NA	
	Risk of bias judgemer	nt		Low	
Bias due to	3.1 Were data for this nearly all, participants		•	N	
missing outcome	3.2 If N/PN/NI to 3.1: not biased by missing		N		
data	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?			PN	
3.4 If Y/PY/NI to 3.3: Is it likely that miss outcome depended on its true value?			-	NA	1
	Risk of bias judgemer	it		Low	
Bias in measure	4.1 Was the method c inappropriate?	of measuring	the outcome	N	

ment of the	4.2 Could measurem outcome have differed			N	
outcome					
outcome	4.3 Were outcome a received by study pa		N		
	4.4 If Y/PY/NI to 4.3:	Could assess	nent of the outcome	NA	
	have been influence	d by knowledg	ge of intervention		
	received?				
	4.5 If Y/PY/NI to 4.4:	•		NA	
	outcome was influer received?	iced by knowle	edge of intervention		
	Risk of bias judgeme	ont		Low	
	hist of bids judgerite			2011	
Bias in	5.1 Were the data th	at produced t	his result analysed in	NI	
selection	accordance with a pr	•			
of the	finalized before unbl	inded outcom	e data were available		
reported	for analysis?				
result	5.2 multiple eligib			NI	
	scales, definitions, ti domain?	me points) wit	thin the outcome		
	5.3 multiple eligibl	le analyses of	the data?	NI	
		ie analyses of			
	Risk of bias judgeme	ent	Some		
			concerns		
Overall	Risk of bias judgeme	ent		Some	
bias				concerns	
Unique ID	M17	Study ID	Mol17	Assessor	
Ref or	Moller (2017)	Aim	assignment to		
Label		AIIII	intervention (the		
			'intention-to-treat'		
			effect)		
Experime	probiotic	Comparat	placebo	Source	
ntal		or	1		
Outcome	PASAT and blood	Results		Weight	1
	pressure				
Domain	Signalling question			Response	Comments
Bias	1.1 Was the allocation	n sequence ra	andom?	Y	
arising		n sequence re			
from the	1.2 Was the allocation	n sequence c	oncealed until	PN	4
randomiz	participants were en	•			
	interventions?				

c	1
Ο	т

ation	1.3 Did baseline differences between intervention	PN	
process	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?		
	Risk of bias judgement	High	
Bias due to	2.1.Were participants aware of their assigned intervention during the trial?	N	
deviation s from intended	2.2.Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	N	
interventi ons	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?	NA	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	РҮ	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	Risk of bias judgement	Low	
Bias due to	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	N	
missing outcome	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	N	
data	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	РҮ	5 subjects in the intervention group
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	PN	discontinued due to gastro-intestinal side effects, however the number of drop- outs is not sufficiently high to claim that the missingness of the data is likely to depends on its true value
	Risk of bias judgement	Some concerns	
Bias in measure	4.1 Was the method of measuring the outcome inappropriate?	N	
ment of	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	

the	4.3 Were outcome as	sessors awar	e of the intervention	PY	
outcome	received by study par	ticipants?			
	4.4 If Y/PY/NI to 4.3: (have been influenced received?		PN		
	4.5 If Y/PY/NI to 4.4: I outcome was influent received?		NA		
	Risk of bias judgemen	nt		Low	
Bias in selection of the reported	5.1 Were the data that accordance with a pre- finalized before unblin for analysis?	e-specified ar	NI		
result	5.2 multiple eligible scales, definitions, tin domain?			NI	
	5.3 multiple eligible	e analyses of	the data?	NI	
	Risk of bias judgemen	nt		Some concerns	
Overall bias	Risk of bias judgemen	nt		High	
Unique	К20	Study ID	Kar20	Assessor	
ID					
Ref or Label	Karbownik (2020)	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	probiotic	Comparat or	placebo	Source	
Outcome	salivary cortisol, metanephrine and pulse rate	Results		Weight	1
Domain	Signalling question			Response	Comments
Bias arising	1.1 Was the allocation		Y		
from the randomiz ation	1.2 Was the allocation participants were enr interventions?	•	Y		
process	1.3 Did baseline differ groups suggest a prob process?			N	

	Risk of bias judgement	Low	
Bias due to	2.1.Were participants aware of their assigned intervention during the trial?	N	
deviation s from intended	2.2.Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	N	
interventi ons	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?	NA	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	PY	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	Risk of bias judgement	Low	
Bias due to	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	N	
missing outcome data	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	PY	ITT = PP analyses
uata	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	Risk of bias judgement	Low	
Bias in measure	4.1 Was the method of measuring the outcome inappropriate?	N	
ment of the outcome	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
outcome	4.3 Were outcome assessors aware of the intervention received by study participants?	N	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	NA	
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	
	Risk of bias judgement	Low	
Bias in selection	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was	NI	

of the	finalized before unblin for analysis?	nded outcom	e data were available		
reported result	5.2 multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?			NI	
	5.3 multiple eligible	analyses of	the data?	NI	
	Risk of bias judgemer	nt		Some concerns	
Overall bias	Risk of bias judgemer	nt		Some concerns	
Unique ID	K09	Study ID	Kit09	Assessor	
Ref or Label	Kitaoka (2009)	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	prebiotic	Comparat or	placebo	Source	
Outcome	salivary cortisol and immunoglobulin A, urinary 8- hydroxydeoxyguano sine	Results		Weight	1
Domain	Signalling question		I	Response	Comments
Bias arising	1.1 Was the allocation	n sequence ra	andom?	NI	
from the randomiz ation	1.2 Was the allocation participants were enrointerventions?	•		NI	
process	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			PN	
	Risk of bias judgement			Some concerns	
Bias due to	2.1.Were participants aware of their assigned intervention during the trial?			N	
deviation s from intended	2.2.Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			N	
interventi ons	2.3. If Y/PY/NI to 2.1 c the intended interven experimental context	tion that aro		NA	

	Risk of bias judgement	Some concerns	
	5.3 multiple eligible analyses of the data?	NI	
result	5.2 multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	NI	
selection of the reported	accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?		
Bias in	Risk of bias judgement5.1 Were the data that produced this result analysed in	Low NI	
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	NA	
outcome	4.3 Were outcome assessors aware of the intervention received by study participants?	N	
ment of the	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
Bias in measure	4.1 Was the method of measuring the outcome inappropriate?	N	
	Risk of bias judgement	High	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NI	1
uald	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NI	
missing outcome data	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	PN	
Bias due to	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	NI	
	Risk of bias judgement	High	No flow diagram
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NI	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	NI	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	

Overall bias	Risk of bias judgemen	t		High	
Unique ID	M04	Study ID	Marcu04	Assessor	
Ref or Label	Marcus (2004)	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	probiotic	Comparat or	placebo	Source	
Outcome	serum cortisol	Results		Weight	1
Domain	Signalling question			Response	Comments
Bias arising	1.1 Was the allocation	sequence ra	andom?	NI	
from the randomiz ation	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			NI	
process	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?		N		
	Risk of bias judgement		Some concerns		
Bias due to	2.1.Were participants intervention during the		eir assigned	РҮ	Study not described as blind/double
deviation s from intended	2.2.Were carers and po aware of participants' trial?	•	•	РҮ	blind
interventi ons	2.3. If Y/PY/NI to 2.1 o the intended intervent experimental context?	ion that aro		N	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?		NA		
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?		NI		
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?		of the failure to	NI	
	Risk of bias judgemen	t		High	

1	1			- <u>1</u>	
Bias due	3.1 Were data for this			Ν	
to	nearly all, participants				
missing	3.2 If N/PN/NI to 3.1: Is there evidence that result was			N	
outcome data	not biased by missing				
	3.3 If N/PN to 3.2: Could missingness in the outcome			PN	
	depend on its true val				
	3.4 If Y/PY/NI to 3.3: I	-	-	NA	
	outcome depended o	n its true val	ue?		
	Risk of bias judgemer	nt		Low	
Bias in	4.1 Was the method o	of measuring	the outcome	Ν	
measure	inappropriate?				
ment of the	4.2 Could measureme			N	
outcome	outcome have differe		0 1		
	4.3 Were outcome as		e of the intervention	PY	
	received by study par	•			
	4.4 If Y/PY/NI to 4.3: (PY	
	have been influenced received?	by knowledg	ge of intervention		
	4.5 If Y/PY/NI to 4.4: I	s it likely the	t assessment of the	PN	
	outcome was influence			FIN	
	received?				
	Risk of bias judgemer	nt		Some	
				concerns	
Bias in	5.1 Were the data tha	at produced t	his result analysed in	NI	
selection	accordance with a pre	•			
of the		nded outcom	e data were available		
reported	for analysis?		. /		
result	5.2 multiple eligible			NI	
	scales, definitions, tim domain?	ie points) wi			
	5.3 multiple eligible	e analyses of	the data?	NI	
		, ,			
	Risk of bias judgemer	nt		Some	
				concerns	
Overall	Risk of bias judgemer	nt		High	
bias				_	
Unique ID	S14	Study ID	Sch14	Assessor	
Ref or	Schmidt (2014)	Aim	assignment to	+ +	
Label	Schmidt (2014)		assignment to intervention (the		
20001			'intention-to-treat'		
			effect)		
			•		

Experime ntal	prebiotic	Comparat or	placebo	Source	Non-commercial trial registry record
iitai					(e.g. ClinicalTrials.gov record)
Outcome	PSS-10, salivary cortisol	Results		Weight	1
Domain	Signalling question			Response	Comments
Bias arising	1.1 Was the allocation	n sequence ra	andom?	NI	
from the randomiz ation	1.2 Was the allocation participants were enricipants?	-		NI	
process	1.3 Did baseline differ groups suggest a prob process?			N	
	Risk of bias judgemer	nt		Some concerns	
Bias due to	2.1.Were participants intervention during th		eir assigned	N	
deviation s from intended	2.2.Were carers and p aware of participants' trial?	•	-	N	
interventi ons	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			NA	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: intended intervention			NA	
	2.6 Was an appropria effect of assignment t	•		N	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?			N	
	Risk of bias judgemer	nt		Some concerns	
Bias due to	3.1 Were data for this nearly all, participants	s randomized	?	N	
missing outcome data	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?			N	
data	3.3 If N/PN to 3.2: Cou depend on its true val	-	NI		
	3.4 If Y/PY/NI to 3.3: I outcome depended o		PN		
	Risk of bias judgemer	nt		Some concerns	

6	9

Bias in	4.1 Was the method o	of measuring	N		
measure	inappropriate?				
ment of the	4.2 Could measureme outcome have differe		N		
outcome	4.3 Were outcome as received by study par		N		
	4.4 If Y/PY/NI to 4.3: 0 have been influenced received?	Could assess	NA		
	4.5 If Y/PY/NI to 4.4: I outcome was influence received?	•	NA		
	Risk of bias judgemer	nt	Low		
Bias in selection of the reported	on accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available			NI	
result	for analysis? 5.2 multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?			NI	
	5.3 multiple eligible analyses of the data?			NI	
	Risk of bias judgemer	nt	Some concerns		
Overall bias	Risk of bias judgement				
Unique ID	К16	Study ID	Kat16	Assessor	
Ref or Label	Kato-Kataoka (2016)	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	probiotic	Comparat or	placebo	Source	Company-owned trial registry record (e.g. GSK Clinical Study Register record)
Outcome	salivary cortisol and alpha amylase, visual analogue stress scale	Results		Weight	1
Domain	Signalling question	•	•	Response	Comments

7	n	
/	υ	

Bias	1.1 Was the allocation sequence random?	PN	
arising from the		 	4
randomiz	1.2 Was the allocation sequence concealed until	NI	
ation	participants were enrolled and assigned to interventions?		
process	1.3 Did baseline differences between intervention	N	
	groups suggest a problem with the randomization		
	process?		
	Risk of bias judgement	Some	
		concerns	
Bias due	2.1.Were participants aware of their assigned	N	
to	intervention during the trial?		
deviation	2.2. Were carers and people delivering the interventions	N	
s from	aware of participants' assigned intervention during the		
intended	trial?		
interventi	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from	NA	
ons	the intended intervention that arose because of the		
	experimental context?		
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	
		V	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	Y	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to	NA	
	analyse participants in the group to which they were		
	randomized?		
	Risk of bias judgement	Low	
Bias due	3.1 Were data for this outcome available for all, or	Y	
to	nearly all, participants randomized?		
missing	3.2 If N/PN/NI to 3.1: Is there evidence that result was	NA	
outcome	not biased by missing outcome data?		
data	3.3 If N/PN to 3.2: Could missingness in the outcome	NA	
	depend on its true value?		
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the	NA	1
	outcome depended on its true value?		
	Risk of bias judgement	Low	
Bias in	4.1 Was the method of measuring the outcome	N	
measure	inappropriate?		
ment of	4.2 Could measurement or ascertainment of the	N	
the	outcome have differed between intervention groups?		
outcome	4.3 Were outcome assessors aware of the intervention	N	
	received by study participants?		
		1	1

	4.4 If Y/PY/NI to 4.3: C have been influenced received?		NA		
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?			NA	
	Risk of bias judgement			Low	
Bias in selection of the reported	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?			NI	
result	5.2 multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?			NI	
	5.3 multiple eligible analyses of the data?			NI	
	Risk of bias judgement			Some concerns	
Overall bias	Risk of bias judgement			Some concerns	
Unique ID	K16b	Study ID	Kat16b	Assessor	
Ref or Label	Kato-Kataoka (2016)	Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experime ntal	probiotic	Comparat or	placebo	Source	
Outcome	salivary cortisol and immunoglobulin A	Results		Weight	1
Domain	Signalling question			Response	Comments
Bias arising from the randomiz ation	participants were enrolled and assigned to			N NI	Based on background data
process	interventions? 1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			N	
	Risk of bias judgement			Some concerns	

Bias due to deviation s from	2.1.Were participants aware of their assigned intervention during the trial?2.2.Were carers and people delivering the interventions aware of participants' assigned intervention during the	N N
intended interventi ons	trial? 2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the	NA
	experimental context? 2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	Y
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA
	Risk of bias judgement	Low
Bias due to	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	N
missing outcome data	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	N
uutu	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	N
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA
	Risk of bias judgement	Low
Bias in measure	4.1 Was the method of measuring the outcome inappropriate?	N
ment of the	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N
outcome	4.3 Were outcome assessors aware of the intervention received by study participants?	N
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	NA
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA
	Risk of bias judgement	Low
Bias in selection of the	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI

reported result	5.2 multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	NI
	5.3 multiple eligible analyses of the data?	NI
	Risk of bias judgement	Some concerns
Overall bias	Risk of bias judgement	Some concerns